PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 14/705, C12N 15/12, 15/63, 15/70, 15/79 — A1

(11) International Publication Number: **WO 99/48921**

(43) International Publication Date: 30 September 1999 (30.09.99)

(21) International Application Number: PCT/US99/06573

(22) International Filing Date: 25 March 1999 (25.03.99)

(30) Priority Data:
60/079,501 — 26 March 1998 (26.03.98) — US

(71) Applicants *(for all designated States except US)*: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Suite 350, 900 Welch Road, Palo Alto, CA 94304 (US). N.V. ORGANON [NL/NL]; Weth, Van Eschstraat 1, P.O. Box 20, NL–5340 BH Oss (NL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HSUEH, Aaron, J., W. [US/US]; 25 Ryan Court, Stanford, CA 94305 (US). HSU, Sheau, Yu [–/US]; Apartment 40, 234 Escuela Avenue, Mountain View, CA 94040 (US). LIANG, Shan–Guang [CN/US]; 438 Ventura Avenue #9, Palo Alto, CA 94306 (US). VAN DER SPEK, Petrus, Johannes [NL/NL]; Bremlaan 10, NL–5342 HM Oss (NL).

(74) Agent: FIELD, Bret, E.; Bozicevic, Field & Francis LLP, Suite 200, 285 Hamilton Avenue, Palo Alto, CA 94301 (US).

(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NOVEL MAMMALIAN G–PROTEIN COUPLED RECEPTORS HAVING EXTRACELLULAR LEUCINE RICH REPEAT REGIONS

(57) Abstract

Isolated nucleotide compositions and sequences are provided for LGR4, LGR5 and LGR7 genes. The nucleic acid compositions find use in identifying homologous or related genes; in identifying endogenous ligands for these receptors; in producing compositions that modulate the expression or function of its encoded protein; for gene therapy; mapping functional regions of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity *in vivo* is used for prophylactic and therapeutic purposes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

NOVEL MAMMALIAN G-PROTEIN COUPLED RECEPTORS HAVING EXTRACELLULAR LEUCINE RICH REPEAT REGIONS

INTRODUCTION

Field of the Invention

The field of this invention is the G-protein coupled receptor family of proteins.

Background

Gonadotropins (Luteinizing hormone, LH; follicle stimulating hormone, FSH; chorionic gonadotropin, CG) and thyrotropin (TSH)) are essential for the growth and differentiation of gonads and thyroid gland, respectively. These glycoprotein hormones bind specific target cell receptors on the plasma membrane to activate the cAMP-protein kinase A pathway.

The receptors for LH, FSH and TSH belong to the large G-protein-coupled, seven-trans-membrane protein family but are unique in having a large N-terminal extra-cellular (ecto-) domain containing leucine-rich repeats important for interaction with large glycoprotein ligands. Studies suggest that in these receptors, the extra-cellular leucine rich repeat region serves as a "baseball glove" which efficiently catches its corresponding large hormone ligand and optimally orients it for interaction with the seven trans-membrane-helical domain of the receptor.

Because hormones and receptors play a prominent role in a variety of physiological processes, there is continued interest in the identification of novel receptors and their ligands, as well as the genes encoding the same.

Relevant Literature

References of interest include: el Tayar, N, "Advances in the Molecular Understanding of Gonadotropins-Receptors Interactions," Mol. Cell. Endocrinol. (December 20, 1996) 125: 65-70; Bhowmick et al., "Determination of Residues Important in Hormone Binding to the Extracellular Domain of the Luteinizing Hormone/Chorionic Gonadotropin Receptor by Site-Directed Mutagenesis and Modeling," Mol. Endocrinol. (September 1996) 10: 1147-1159; Thomas et al., "Mutational Analyses of the Extracellular Domain of the Full-Length Lutropin/Choriogonadotropin Receptor Suggest Leucine-Rich Repeats 1-6 are Involved in Hormone Binding," Mol. Endocrinol. (June 1996) 10:760-768; Segaloff & Ascoli, "The Gonadotropin Receptors: Insights from the

Cloning of their cDNAs." Oxf. Rev. Reprod. Biol. (1992) 14: 141-168; Braun et al., "Amino-Terminal Leucine-Rich Repeats in Gonadotropin Receptors Determine Hormone Selectivity," EMBO J (July 1991) 10: 1885-1890; and Segaloff et al., "Structure of the Lutropin/Choriogonadotropin Receptor," Recent Prog. Horm. Res. (1990) 46: 261-301.

SUMMARY OF THE INVENTION

Three novel mammalian G-protein coupled receptors having extra-cellular leucine rich repeat domains, i.e. LGR4, LGR5 and LGR7, and polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. The subject proteins, polypeptide and nucleic acid compositions find use in a variety of different applications, including the identification of homologous or related genes; the production of compositions that modulate the expression or function of the subject proteins; in the identification of endogenous ligands for the subject orphan receptors; in the generation of functional binding proteins for the neutralization of the actions of endogenous ligands; in gene therapy; in mapping functional regions of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity *in vivo* is used for prophylactic and therapeutic purposes, and the like.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 provides the nucleotide and amino acid sequence for human LGR4.

Fig. 2 provides the nucleotide and amino acid sequence for human LGR5.

Fig. 3 provides the nucleotide and amino acid sequence for human LGR7, long form.

Fig. 4 provides the nucleotide and amino acid sequence for human LGR7, short form.

Fig. 5 provides an alignment comparison of the long and short forms of LGR7.

Figs. 6 provides a comparison of deduced amino acid sequence of LGR4 and 5 cDNAs and those encoding FSH and LH receptors.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Novel mammalian G-protein coupled receptors having extra-cellular leucine rich repeat regions (i.e. LGR4, LGR5 and LGR7) and polypeptide compositions related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and/or nucleic acid compositions find use in a variety of different applications, including the identification of homologous or related genes; for the identification of endogenous ligands for these novel receptors; the production of compositions that modulate the expression or function of the receptors; for gene therapy; for mapping functional regions of the receptors; in studying associated physiological pathways; for *in vivo* prophylactic and therapeutic purposes; as immunogens for producing antibodies; in screening for biologically active agents; and the like.

Before the subject invention is further described, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

In this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

CHARACTERIZATION OF LGR4, LGR5 AND LGR7

LGR4, LGR5 and LGR7 are novel mammalian receptors of the G-protein coupled, seven trans-membrane family of proteins, specifically the subfamily of G-protein coupled seven trans-membrane proteins which are characterized by the presence of extra-cellular leucine rich repeat regions. As such, these proteins have trans-membrane segments and extra-cellular regions similar to those found in the known LH, FSH, and TSH receptors. In other words, these proteins have both a G-protein coupled seven trans-membrane region

and a leucine rich repeat extra-cellular domain. The N-terminal extra-cellular domains of these proteins also show high homology with Drosophila Slit and Toll proteins having leucine rich repeats. These proteins are expressed in diverse tissues.

The human LGR4 gene has a nucleotide sequence as shown in SEQ ID NO:01. The human LGR4 gene product has an amino acid sequence as shown in SEQ ID NO:02. LGR4 is expressed in a plurality of different tissue types, including ovary, testis, adrenal, placenta, liver, kidney and intestine.

The human LGR5 gene has a nucleotide sequence as shown in SEQ ID NO:03. The LGR5 gene product has an amino acid sequence as shown in SEQ ID NO:04. LGR5 has been found to be mainly expressed in muscle, placenta and spinal cord tissue.

The human LGR7 gene encodes multiple splicing variants, each of which contains a multitude of cysteine-rich low density lipoprotein (LDL) binding motifs at the N-terminus in addition to the luecine rich repeat region. The longer forms of LGR-7 have a higher similarity than shorter froms of LGR-7 to snail LGR in the trans-membrane domain and the N-terminal LDL binding domain. The overall structure of both the long and short forms of LGR-7 is similar to that of the LH receptor. The human LGR7 short form gene has a nucleotide sequence as shown in SEQ ID NO:05. The LGR7 short form gene product has an amino acid sequence as shown in SEQ ID NO:06. The human LGR7 long form gene has a nucleotide sequence as shown in SEQ ID NO:07. The LGR7 long form gene product has an amino acid sequence as shown in SEQ ID NO:08. LGR7 is expressed in multiple tissues, including testis, ovary, prostate, intestine and colon.

IDENTIFICATION OF *LGR4, LGR5 AND LGR7* SEQUENCES

Homologs of *LGR4, LGR5 and LGR7* are identified by any of a number of methods. A fragment of the provided cDNA may be used as a hybridization probe against a cDNA library from the target organism of interest, where low stringency conditions are used. The probe may be a large fragment, or one or more short degenerate primers.

Nucleic acids having sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 6×SSC (0.9 M sodium chloride/0.09 M sodium citrate) and remain bound when subjected to washing at 55°C in 1×SSC (0.15 M sodium chloride/0.015 M sodium citrate). Sequence identity may be determined by

hybridization under stringent conditions, for example, at 50°C or higher and 0.1×SSC (15 mM sodium chloride/01.5 mM sodium citrate). Nucleic acids having a region of substantial identity to the provided *LGR4*, *LGR5* and or *LGR7* sequences, e.g. allelic variants, genetically altered versions of the gene, etc., bind to the provided sequences under stringent hybridization conditions. By using probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes. The source of homologous genes may be any species, e.g., primate species, particularly human; rodents, such as rats and mice; canines; felines; bovines; ovines; equines; yeast; nematodes; etc.

Between mammalian species, *e.g.*, human and mouse, homologs have substantial sequence similarity, *e.g.* at least 75% sequence identity, usually at least 90%, more usually at least 95% between nucleotide sequences. Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, coding region, flanking region, *etc.* A reference sequence will usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul *et al.* (1990), *J. Mol. Biol.* **215**:403-10. Unless specified otherwise, all sequence analysis numbers provided herein are as determined with the BLAST program using default settings. The sequences provided herein are essential for recognizing *LGR4*, *LGR5* and *LGR7*-related and homologous proteins in database searches.

LGR4, *LGR5* and *LGR7* NUCLEIC ACID COMPOSITIONS

Nucleic acids encoding LGR4, LGR5 and LGR7 may be cDNA or genomic DNA or a fragment thereof. The terms "*LGR4* gene," "*LGR5* gene" and "*LGR7* gene" shall be intended to mean the open reading frame encoding specific LGR4, LGR5 and LGR7 polypeptides, and *LGR4*, *LGR5* and *LGR7* introns, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The gene may be introduced into an appropriate vector for extra-chromosomal maintenance or for integration into a host genome.

The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, removed by nuclear RNA splicing, to create a continuous open reading frame encoding an LGR4, LGR5 and LGR7 protein.

A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It may further include the 3' and 5' untranslated regions found in the mature mRNA. It may further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, *etc.*, including about 1 kb, but possibly more, of flanking genomic DNA at either the 5 ' or 3' end of the transcribed region. The genomic DNA may be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3' or 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue and stage specific expression.

The sequence of the 5' flanking region may be utilized for promoter elements, including enhancer binding sites, that provide for developmental regulation in tissues where *LGR4*, *LGR5* and/or *LGR7* is expressed. The tissue specific expression is useful for determining the pattern of expression, and for providing promoters that mimic the native pattern of expression. Naturally occurring polymorphisms in the promoter region are useful for determining natural variations in expression, particularly those that may be associated with disease.

Alternatively, mutations may be introduced into the promoter region to determine the effect of altering expression in experimentally defined systems. Methods for the identification of specific DNA motifs involved in the binding of transcriptional factors are known in the art, *e.g.* sequence similarity to known binding motifs, gel retardation studies, *etc.* For examples, see Blackwell *et al.* (1995), *Mol. Med.* **1**:194-205; Mortlock *et al.* (1996), *Genome Res.* **6**:327-33; and Joulin and Richard-Foy (1995), *Eur. J. Biochem.* **232**:620-626.

The regulatory sequences may be used to identify *cis* acting sequences required for transcriptional or translational regulation of *LGR4, LGR5* and/or *LGR7* expression, especially in different tissues or stages of development, and to identify *cis* acting sequences and *trans*-acting factors that regulate or mediate *LGR4, LGR* and/or *LGR7* expression. Such transcription or translational control regions may be operably linked to an *LGR4, LGR5* or *LGR7* gene in order to promote expression of wild type or altered LGR4, LGR5 or LGR7 or other proteins of interest in cultured cells, or in embryonic, fetal or adult tissues, and for gene therapy.

The nucleic acid compositions of the subject invention may encode all or a part of the subject polypeptides. Double or single stranded fragments may be obtained of the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, *etc.* For the most part, DNA fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and may be at least about 50 nt. Such small DNA fragments are useful as primers for PCR, hybridization screening probes, *etc.* Larger DNA fragments, *i.e.* greater than 100 nt are useful for production of the encoded polypeptide. For use in amplification reactions, such as PCR, a pair of primers will be used. The exact composition of the primer sequences is not critical to the invention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art. It is preferable to choose a pair of primers that will generate an amplification product of at least about 50 nt, preferably at least about 100 nt. Algorithms for the selection of primer sequences are generally known, and are available in commercial software packages. Amplification primers hybridize to complementary strands of DNA, and will prime towards each other.

The *LGR4, LGR* and *LGR7* genes are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include an *LGR4, LGR5* or *LGR7* sequence or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", *i.e.* flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome.

The DNA may also be used to identify expression of the gene in a biological specimen. The manner in which one probes cells for the presence of particular nucleotide

sequences, as genomic DNA or RNA, is well established in the literature and does not require elaboration here. DNA or mRNA is isolated from a cell sample. The mRNA may be amplified by RT-PCR, using reverse transcriptase to form a complementary DNA strand, followed by polymerase chain reaction amplification using primers specific for the subject DNA sequences. Alternatively, the mRNA sample is separated by gel electrophoresis, transferred to a suitable support, *e.g.* nitrocellulose, nylon, *etc.*, and then probed with a fragment of the subject DNA as a probe. Other techniques, such as oligonucleotide ligation assays, *in situ* hybridizations, and hybridization to DNA probes arrayed on a solid chip may also find use. Detection of mRNA hybridizing to the subject sequence is indicative of *LGR4, LGR5* and/or *LGR7* gene expression in the sample.

The sequence of an *LGR4, LGR5* or *LGR7* gene, including flanking promoter regions and coding regions, may be mutated in various ways known in the art to generate targeted changes in promoter strength, sequence of the encoded protein, *etc.* The DNA sequence or protein product of such a mutation will usually be substantially similar to the sequences provided herein, *i.e.* will differ by at least one nucleotide or amino acid, respectively, and may differ by at least two but not more than about ten nucleotides or amino acids. The sequence changes may be substitutions, insertions, deletions, or a combination thereof. Deletions may further include larger changes, such as deletions of a domain or exon. Other modifications of interest include epitope tagging, *e.g.* with the FLAG system, HA, *etc.* For studies of subcellular localization, fusion proteins with green fluorescent proteins (GFP) may be used.

Techniques for *in vitro* mutagenesis of cloned genes are known. Examples of protocols for site specific mutagenesis may be found in Gustin *et al. (1993), Biotechniques* **14**:22; Barany (1985), *Gene* **37**:111-23; Colicelli *et al. (1985), Mol. Gen. Genet.* **199**:537-9; and Prentki *et al.* (1984), *Gene* **29**:303-13. Methods for site specific mutagenesis can be found in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, CSH Press 1989, pp. 15.3-15.108; Weiner *et al.* (1993), *Gene* **126**:35-41; Sayers *et al.* (1992), *Biotechniques* **13**:592-6; Jones and Winistorfer (1992), *Biotechniques* **12**:528-30; Barton *et al.* (1990), *Nucleic Acids Res* **18**:7349-55; Marotti and Tomich (1989), *Gene Anal. Tech.* **6**:67-70; and Zhu (1989), *Anal Biochem* **177**:120-4. Such mutated genes may

be used to study structure-function relationships of LGR4, LGR5 and/or LGR7, or to alter properties of the protein that affect its function or regulation.

LGR4, LGR5 and LGR7 Polypeptides

Also provided by the subject invention are LGR4, LGR5 and LGR7 polypeptide compositions. The term polyeptide composition as used herein refers to both the full length proteins as well as portions or fragments thereof. Also included in this term are variations of the naturally occurring proteins, where such variations are homologous or substantially similar to the naturally occurring protein, be the naturally occurring protein the human protein, mouse protein, or protein from some other species which naturally expresses an LGR4, LGR5 or LGR7 protein, usually a mammalian species. A candidate homologous protein is substantially similar to an LGR4, LGR5 or LGR7 protein of the subject invention, and therefore is an LGR4, LGR5 or LGR7 protein of the subject invention, if the candidate protein has a sequence that has at least about 80%, usually at least about 90% and more usually at least about 98% sequence identity with an LGR4, LGR5 or LGR7 protein, as measured by BLAST, supra. In the following description of the subject invention, the term "LGR4, LGR5 or LGR7-protein" is used to refer not only to the human LGR4, LGR5 or LGR7 protein, but also to homologs thereof expressed in non-human species, e.g. murine, rat and other mammalian species.

The subject gene may be employed for producing all or portions of LGR4, LGR5 and LGR7 polypeptides. By "LGR4 polypeptide/protein", "LGR5 polypeptide/protein," and "LGR7 polypeptide/protein" is meant an amino acid sequence encoded by an open reading frame (ORF) of *LGR4*, *LGR5* and *LGR7* genes, including the full-length native polypeptide and fragments thereof, particularly biologically active fragments and/or fragments corresponding to functional domains, e.g. extra-cellular regions; and including fusions of the subject polypeptides to other proteins or parts thereof, e.g. chimeric proteins. For expression, an expression cassette may be employed. The expression vector will provide a transcriptional and translational initiation region, which may be inducible or constitutive, where the coding region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination

region. These control regions may be native to an *LGR4*, *LGR5* or *LGR7* gene, or may be derived from exogenous sources.

Expression vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding heterologous proteins. A selectable marker operative in the expression host may be present. Expression vectors may be used for the production of fusion proteins, where the exogenous fusion peptide provides additional functionality, i.e. increased protein synthesis, stability, reactivity with defined antisera, an enzyme marker, e.g. β-galactosidase, etc.

Expression cassettes may be prepared comprising a transcription initiation region, the gene or fragment thereof, and a transcriptional termination region. Of particular interest is the use of sequences that allow for the expression of functional epitopes or domains, usually at least about 8 amino acids in length, more usually at least about 15 amino acids in length, to about 25 amino acids, and up to the complete open reading frame of the gene. After introduction of the DNA, the cells containing the construct may be selected by means of a selectable marker, the cells expanded and then used for expression.

LGR4, LGR5 or LGR7 polypeptides may be expressed in prokaryotes or eukaryotes in accordance with conventional ways, depending upon the purpose for expression. For large scale production of the protein, a unicellular organism, such as *E. coli*, *B. subtilis*, *S. cerevisiae*, insect cells in combination with baculovirus vectors, or cells of a higher organism such as vertebrates, particularly mammals, *e.g.* COS 7 cells, may be used as the expression host cells. In some situations, it is desirable to express the *LGR4*, *LGR5* or *LGR7* gene in eukaryotic cells, where the LGR4, LGR5 or LGR7 protein will benefit from native folding and post-translational modifications. Small peptides can also be synthesized in the laboratory. Polypeptides that are subsets of the complete LGR4, LGR5 or LGR7 sequence may be used to identify and investigate parts of the protein important for function or to raise antibodies directed against these regions.

For production of the extracellular domain of the LGR4, LGR5 or LGR7 receptor, the anchored receptor approach as described in Osuga et al, Mol. Endocrinol. (1997) 11: 1659-1668 may be employed. Likewise, the chimeric receptor approach described in Kudo et al. J Biol. Chem. (1996) 271: 22470-22478 may be used.

Such peptides find use in the identification of endogenous ligands and in drug screening for agonists and atangonists using methods described in Osuga, supra. Solubilized extracellular domains find use as therapeutic agents, e.g. in the neutralization of the action of endogenous ligands.

With the availability of the protein or fragments thereof in large amounts, by employing an expression host, the protein may be isolated and purified in accordance with conventional ways. A lysate may be prepared of the expression host and the lysate purified using HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, or other purification technique. The purified protein will generally be at least about 80% pure, preferably at least about 90% pure, and may be up to and including 100% pure. Pure is intended to mean free of other proteins, as well as cellular debris.

The expressed LGR4, LGR5 and LGR7 polypeptides are useful for the production of antibodies, where short fragments provide for antibodies specific for the particular polypeptide, and larger fragments or the entire protein allow for the production of antibodies over the surface of the polypeptide. Antibodies may be raised to the wild-type or variant forms of LGR4, LGR5 or LGR7. Antibodies may be raised to isolated peptides corresponding to these domains, or to the native protein.

Antibodies are prepared in accordance with conventional ways, where the expressed polypeptide or protein is used as an immunogen, by itself or conjugated to known immunogenic carriers, *e.g.* KLH, pre-S HBsAg, other viral or eukaryotic proteins, or the like. Various adjuvants may be employed, with a series of injections, as appropriate. Both polyclonal and monoclonal antibodies may be produced. For monoclonal antibodies, after one or more booster injections, the spleen is isolated, the lymphocytes immortalized by cell fusion, and then screened for high affinity antibody binding. The immortalized cells, *i.e.* hybridomas, producing the desired antibodies may then be expanded. For further description, see Monoclonal Antibodies: A Laboratory Manual, Harlow and Lane eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, New York, 1988. If desired, the mRNA encoding the heavy and light chains may be isolated and mutagenized by cloning in *E. coli*, and the heavy and light chains mixed to further enhance the affinity of the antibody. Alternatives to *in vivo* immunization as a

method of raising antibodies include binding to phage "display" libraries, usually in conjunction with *in vitro* affinity maturation.

DIAGNOSTIC USES

The subject nucleic acid and/or polypeptide compositions may be used to analyze a patient sample for the presence of polymorphisms associated with a disease state or genetic predisposition to a disease state. Biochemical studies may be performed to determine whether a sequence polymorphism in an *LGR4, LGR* or *LGR7*coding region or control regions is associated with disease. Disease associated polymorphisms may include deletion or truncation of the gene, mutations that alter expression level, that affect the activity of the protein, and the like.

Changes in the promoter or enhancer sequence that may affect expression levels of *LGR4, LGR5* or *LGR7* can be compared to expression levels of the normal allele by various methods known in the art. Methods for determining promoter or enhancer strength include quantitation of the expressed natural protein; insertion of the variant control element into a vector with a reporter gene such as β-galactosidase, luciferase, chloramphenicol acetyltransferase, *etc.*, that provides for convenient quantitation; and the like.

A number of methods are available for analyzing nucleic acids for the presence of a specific sequence, *e.g.* a disease associated polymorphism. Where large amounts of DNA are available, genomic DNA is used directly. Alternatively, the region of interest is cloned into a suitable vector and grown in sufficient quantity for analysis. Cells that express LGR4, LGR5 or LGR7 may be used as a source of mRNA, which may be assayed directly or reverse transcribed into cDNA for analysis. The nucleic acid may be amplified by conventional techniques, such as the polymerase chain reaction (PCR), to provide sufficient amounts for analysis. The use of the polymerase chain reaction is described in Saiki, *et al.* (1985), *Science* **239**:487, and a review of techniques may be found in Sambrook, *et al.* Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp.14.2–14.33. Alternatively, various methods are known in the art that utilize oligonucleotide ligation as a means of detecting polymorphisms, for examples see Riley *et al.* (1990),

Nucl. Acids Res. **18**:2887-2890; and Delahunty *et al.* (1996), *Am. J. Hum. Genet.* **58**:1239-1246.

A detectable label may be included in an amplification reaction. Suitable labels include fluorochromes, *e.g.* fluorescein isothiocyanate (FITC), rhodamine, Texas Red, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy-X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM) or N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), radioactive labels, *e.g.* ^{32}P, ^{35}S, ^{3}H; *etc.* The label may be a two stage system, where the amplified DNA is conjugated to biotin, haptens, *etc.* having a high affinity binding partner, *e.g.* avidin, specific antibodies, *etc.*, where the binding partner is conjugated to a detectable label. The label may be conjugated to one or both of the primers. Alternatively, the pool of nucleotides used in the amplification is labeled, so as to incorporate the label into the amplification product.

The sample nucleic acid, *e.g.* amplified or cloned fragment, is analyzed by one of a number of methods known in the art. The nucleic acid may be sequenced by dideoxy or other methods, and the sequence of bases compared to a wild-type *LGR4*, *LGR5* or *LGR7* sequence. Hybridization with the variant sequence may also be used to determine its presence, by Southern blots, dot blots, *etc.* The hybridization pattern of a control and variant sequence to an array of oligonucleotide probes immobilized on a solid support, as described in US 5,445,934, or in WO 95/35505 (the disclosures of which are herein incorporated by reference), may also be used as a means of detecting the presence of variant sequences. Single strand conformational polymorphism (SSCP) analysis, denaturing gradient gel electrophoresis (DGGE), and heteroduplex analysis in gel matrices are used to detect conformational changes created by DNA sequence variation as alterations in electrophoretic mobility. Alternatively, where a polymorphism creates or destroys a recognition site for a restriction endonuclease, the sample is digested with that endonuclease, and the products size fractionated to determine whether the fragment was digested. Fractionation is performed by gel or capillary electrophoresis, particularly acrylamide or agarose gels.

Screening for mutations in *LGR4*, *LGR5* or *LGR7* may be based on the functional or antigenic characteristics of the protein. Protein truncation assays are useful in detecting

deletions that may affect the biological activity of the protein. Various immunoassays designed to detect polymorphisms in LGR4, LGR5 or LGR7 proteins may be used in screening. Where many diverse genetic mutations lead to a particular disease phenotype, functional protein assays have proven to be effective screening tools. The activity of the encoded LGR4, LGR5 or LGR7 protein may be determined by comparison with the wild-type protein.

Antibodies specific for LGR4, LGR5 or LGR7 proteins may be used in staining or in immunoassays. Samples, as used herein, include biological fluids such as semen, blood, cerebrospinal fluid, tears, saliva, lymph, dialysis fluid and the like; organ or tissue culture derived fluids; and fluids extracted from physiological tissues. Also included in the term are derivatives and fractions of such fluids. The cells may be dissociated, in the case of solid tissues, or tissue sections may be analyzed. Alternatively a lysate of the cells may be prepared.

Diagnosis may be performed by a number of methods to determine the absence or presence or altered amounts of normal or abnormal LGR4, LGR5 or LGR7 in patient cells. For example, detection may utilize staining of cells or histological sections, performed in accordance with conventional methods. Cells are permeabilized to stain cytoplasmic molecules. The antibodies of interest are added to the cell sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody may be labeled with radioisotopes, enzymes, fluorescers, chemiluminescers, or other labels for direct detection. Alternatively, a second stage antibody or reagent is used to amplify the signal. Such reagents are well known in the art. For example, the primary antibody may be conjugated to biotin, with horseradish peroxidase-conjugated avidin added as a second stage reagent. Alternatively, the secondary antibody conjugated to a flourescent compound, *e.g.* fluorescein, rhodamine, Texas red, *etc.* Final detection uses a substrate that undergoes a color change in the presence of the peroxidase. The absence or presence of antibody binding may be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, *etc.*

Diagnostic screening may also be performed for polymorphisms that are genetically linked to a disease predisposition, particularly through the use of microsatellite

markers or single nucleotide polymorphisms. Frequently the microsatellite polymorphism itself is not phenotypically expressed, but is linked to sequences that result in a disease predisposition. However, in some cases the microsatellite sequence itself may affect gene expression. Microsatellite linkage analysis may be performed alone, or in combination with direct detection of polymorphisms, as described above. The use of microsatellite markers for genotyping is well documented. For examples, see Mansfield *et al.* (1994), *Genomics* **24**:225-233; Ziegle *et al.* (1992), *Genomics* **14**:1026-1031; Dib *et al.*, *supra*.

MODULATION OF *LGR4*, *LGR5* and *LGR7* GENE EXPRESSION

The *LGR4*, *LGR5* or *LGR7* genes, gene fragments, or the LGR4, LGR5 or LGR7 protein or protein fragments, are useful in gene therapy to treat disorders associated with *LGR4*, *LGR5* or *LGR7* defects. Expression vectors may be used to introduce the *LGR4*, *LGR5* or *LGR7* gene into a cell. Such vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences. Transcription cassettes may be prepared comprising a transcription initiation region, the target gene or fragment thereof, and a transcriptional termination region. The transcription cassettes may be introduced into a variety of vectors, *e.g.* plasmid; retrovirus, *e.g.* lentivirus; adenovirus; and the like, where the vectors are able to transiently or stably be maintained in the cells, usually for a period of at least about one day, more usually for a period of at least about several days to several weeks.

The gene or LGR4, LGR5 or LGR7 protein may be introduced into tissues or host cells by any number of routes, including viral infection, microinjection, or fusion of vesicles. Jet injection may also be used for intramuscular administration, as described by Furth *et al.* (1992), *Anal Biochem* **205**:365-368. The DNA may be coated onto gold microparticles, and delivered intradermally by a particle bombardment device, or "gene gun" as described in the literature (see, for example, Tang *et al.* (1992), *Nature* **356**:152-154), where gold microprojectiles are coated with the *LGR4*, *LGR5* or *LGR7* DNA, then bombarded into skin cells.

Antisense molecules can be used to down-regulate expression of *LGR4*, *LGR5*, or *LGR7* in cells. The anti-sense reagent may be antisense oligonucleotides (ODN), particularly synthetic ODN having chemical modifications from native nucleic acids, or

nucleic acid constructs that express such anti-sense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products. Antisense molecules inhibit gene expression through various mechanisms, *e.g.* by reducing the amount of mRNA available for translation, through activation of RNAse H, or steric hindrance. One or a combination of antisense molecules may be administered, where a combination may comprise multiple different sequences.

Antisense molecules may be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the antisense molecule is a synthetic oligonucleotide. Antisense oligonucleotides will generally be at least about 7, usually at least about 12, more usually at least about 20 nucleotides in length, and not more than about 500, usually not more than about 50, more usually not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, specificity, including absence of cross-reactivity, and the like. It has been found that short oligonucleotides, of from 7 to 8 bases in length, can be strong and selective inhibitors of gene expression (see Wagner *et al.* (1996), *Nature Biotechnol.* **14**:840-844).

A specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence. Selection of a specific sequence for the oligonucleotide may use an empirical method, where several candidate sequences are assayed for inhibition of expression of the target gene in an *in vitro* or animal model. A combination of sequences may also be used, where several regions of the mRNA sequence are selected for antisense complementation.

Antisense oligonucleotides may be chemically synthesized by methods known in the art (see Wagner *et al.* (1993), *supra*, and Milligan *et al.*, *supra*.) Preferred oligonucleotides are chemically modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A number of such modifications have been described in the literature, which alter the chemistry of the backbone, sugars or heterocyclic bases.

Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur;

phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3'-O'-5'-S-phosphorothioate, 3'-S-5'-O-phosphorothioate, 3'-CH_2-5'-O-phosphonate and 3'-NH-5'-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage. Sugar modifications are also used to enhance stability and affinity. The α-anomer of deoxyribose may be used, where the base is inverted with respect to the natural β-anomer. The 2'-OH of the ribose sugar may be altered to form 2'-O-methyl or 2'-O-allyl sugars, which provides resistance to degradation without comprising affinity. Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2'-deoxycytidine and 5-bromo-2'-deoxycytidine for deoxycytidine. 5- propynyl-2'-deoxyuridine and 5-propynyl-2'-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

As an alternative to anti-sense inhibitors, catalytic nucleic acid compounds, *e.g.* ribozymes, anti-sense conjugates, *etc.* may be used to inhibit gene expression. Ribozymes may be synthesized *in vitro* and administered to the patient, or may be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (for example, see International patent application WO 9523225, and Beigelman *et al.* (1995), *Nucl. Acids Res.* **23**:4434-42). Examples of oligonucleotides with catalytic activity are described in WO 9506764. Conjugates of anti-sense ODN with a metal complex, *e.g.* terpyridylCu(II), capable of mediating mRNA hydrolysis are described in Bashkin *et al.* (1995), *Appl. Biochem. Biotechnol.* **54**:43-56.

GENETICALLY ALTERED CELL OR ANIMAL MODELS FOR LGR4, LGR5 AND LGR7 FUNCTION

The subject nucleic acids can be used to generate transgenic, non-human animals or site specific gene modifications in cell lines. Transgenic animals may be made through homologous recombination, where the normal *LGR4, LGR5* or *LGR7* locus is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like.

The modified cells or animals are useful in the study of *LGR4*, *LGR5* and/or *LGR7* function and regulation. For example, a series of small deletions and/or substitutions may be made in the host's native *LGR4*, *LGR5* or *LGR7* gene to determine the role of different exons. Of interest is the use of *LGR4*, *LGR5* or *LGR7* to construct transgenic animal models for disease states. Specific constructs of interest include anti-sense *LGR4*, *LGR5* or *LGR7*, which will block LGR4, LGR5 or LGR7 expression, expression of dominant negative *LGR4*, *LGR5* or *LGR7* mutations, and over-expression of *LGR4*, *LGR5* or *LGR7* genes. Where an *LGR4*, *LGR5* or *LGR7* sequence is introduced, the introduced sequence may be either a complete or partial sequence of an *LGR4*, *LGR5* or *LGR7* gene native to the host, or may be a complete or partial *LGR4*, *LGR5* or *LGR7* sequence that is exogenous to the host animal, *e.g.*, a human *LGR4*, *LGR5* or *LGR7* sequence. A detectable marker, such as *lac Z* may be introduced into the *LGR4*, *LGR5* or *LGR7* locus, where upregulation of *LGR4*, *LGR5* or *LGR7* expression will result in an easily detected change in phenotype.

One may also provide for expression of the *LGR4*, *LGR5* or *LGR7* gene or variants thereof in cells or tissues where it is not normally expressed, at levels not normally present in such cells or tissues, or at abnormal times of development. By providing expression of LGR4, LGR5 or LGR7 protein in cells in which it is not normally produced, one can induce changes in cell behavior, *e.g.* through LGR4, LGR5 or LGR7 mediated activity.

DNA constructs for homologous recombination will comprise at least a portion of the LGR4, LGR5 or LGR7 gene, which may or may not be native to the species of the host animal, wherein the gene has the desired genetic modification(s), and includes regions of homology to the target locus. DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for positive and negative selection are included. Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. For various techniques for transfecting mammalian cells, see Keown *et al.* (1990), *Meth. Enzymol.* **185:**527-537.

For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, *e.g.* mouse, rat, guinea pig, *etc.* Such cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of leukemia

inhibiting factor (LIF). When ES or embryonic cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting offspring screened for the construct. By providing for a different phenotype of the blastocyst and the genetically modified cells, chimeric progeny can be readily detected.

The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in *in vitro* culture. The transgenic animals may be any non-human mammal, such as laboratory animals, domestic animals, etc. The transgenic animals may be used in functional studies, drug screening, *etc.*, *e.g.* to determine the effect of a candidate drug on *LGR4*, *LGR5* or *LGR7*or related gene activation *etc.*

IN VITRO MODELS FOR LGR4, LGR5 or LGR7 FUNCTION

The availability of a number of components in the G-protein coupled receptor family, as previously described, allows *in vitro* reconstruction of the processes or systems in which members of this family operate. Two or more of the components, such as the isolated receptor and a potential ligand therefore, may be combined *in vitro*, and the behavior assessed in terms of activation of transcription of specific target sequences; modification of protein components, *e.g.* proteolytic processing, phosphorylation, methylation, *etc.*; ability of different protein components to bind to each other. The components may be modified by sequence deletion, substitution, *etc.* to determine the functional role of specific domains.

Drug screening may be performed using an *in vitro* model, a genetically altered cell or animal, purified LGR4, LGR5 or LGR7 protein, as well as fragments or portions thereof, e.g. solubilized extra-cellular domain or chimeric receptor proteins comprising the LGR4, LGR5 or LGR7 extra-cellular domain. One can identify ligands or substrates that bind to and modulate the action of LGR4, LGR5 or LGR7. Areas of investigation include the development of agents that beneficially counter abnormalities related to LGR4, LGR5 or LGR7 and the use of such agents in the therapy.

Drug screening identifies agents that modulate the activity of LGR4, LGR5 or LGR7 function in abnormal cells. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, and the like. The purified protein may also be used for determination of three-dimensional crystal structure, which can be used for modeling intermolecular interactions, such as GTP binding, *etc.*

The term "agent" as used herein describes any molecule, *e.g.* protein or pharmaceutical, with the capability of altering or mimicking the physiological function of LGR4, LGR5 or LGR7. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, *i.e.* at zero concentration or below the level of detection.

In some embodiments, candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, *etc.* to produce structural analogs.

Of particular interest in certain embodiments are peptidic agents based on LGR4, LGR5 or LGR7, e.g. solubilized extra-cellular domain or chimeric receptor proteins comprising the LGR4, LGR5 or LGR7 extra-cellular domain, where such agents neutralize the activity of endogenous LGR4, LGR5 or LGR7 ligands, e.g. hormones.

Where the screening assay is a binding assay, one or more of the molecules may be joined to a label, where the label can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemiluminescers, enzymes, specific binding molecules, particles, *e.g.* magnetic particles, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule that provides for detection, in accordance with known procedures.

A variety of other reagents may be included in the screening assay. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc., that are used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, *etc.*, may be used. The mixture of components are added in any order that provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4 and 40°C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening. Typically between 0.1 and 1 hours will be sufficient.

Other assays of interest detect agents that mimic LGR4, LGR5 or LGR7 function. For example, an expression construct comprising an *LGR4, LGR5* or *LGR7* gene may be introduced into a cell line under conditions that allow expression. The level of LGR4, LGR5 or LGR7 activity is determined by a functional assay, as previously described. In one screening assay, the ability of candidate agents to inhibit or enhance LGR4, LGR5 or LGR7 function is determined. Alternatively, candidate agents are added to a cell that lacks functional LGR4, LGR5 or LGR7, and screened for the ability to reproduce LGR4, LGR5 or LGR7 activity in a functional assay.

The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host for treatment, *etc.* The compounds may also be used to enhance *LGR4, LGR5* or *LGR7* function. The inhibitory agents may be administered in a variety of ways, orally, topically, parenterally *e.g.* subcutaneously, intraperitoneally, by viral infection, intravascularly, *etc.* Topical treatments are of particular interest. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%.

The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically-active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents.

EXPERIMENTAL

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention. Efforts have been made to ensure accuracy with respect to the numbers used (*e.g.* amounts, temperature, concentrations, *etc.*) but some experimental errors and deviations

should be allowed for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees centigrade; and pressure is at or near atmospheric.

Example 1. Identification of LGR4 and LGR5

Human sequences related to the sea anemone and Drosophila glycoprotein hormone receptors were identified from the expression sequence tag database (dbEST) at the National Center for Biotechnology Information by using the BLAST server with the BLOSUM62 protein comparison matrix (Altschul SF *et al*, Nucleic Acids Res (1997) 25:3389-3402). Human ESTs showing high homology to two non-overlapping regions of the gonadotropin receptors were identified. Clones AA312798 and AA298810 were found to encode transmembrane four to five of the putative receptor LGR4 whereas AA460529 and AA424098 encode transmembrane two to three of the putative receptor LGR5. Using these ESTs to further search the GenBank EST division database, overlapping EST sequences were aligned to obtain the longest open reading frame (ORF) for these receptors.

Based on the longest human ORF, specific primers were designed for PCR amplification of LGR4 and LGR5 cDNA fragments from rat ovary and human placenta, respectively. After hybridization with labeled EST clones and confirmation of DNA sequences by dideoxy DNA sequencing, specific receptor fragments isolated were used to design primers to prepare sub-cDNA libraries enriched with specific receptor cDNAs. For 5′ extension, reverse transcription was performed using rat ovarian and human placenta mRNA preparations and receptor-specific primers. Following second strand synthesis, the enriched cDNA pool was tailed at 5′-ends with specific adaptor sequences to allow further PCR amplification. For 3′ extension, rat ovarian or human placenta mRNAs were reversed transcribed using oligo-dT, followed by second strand synthesis using receptor-specific primers and adaptor tailing. These mini-libraries were further used as templates for PCR amplification of upstream or downstream cDNAs specific for each receptor using internal primers. PCR products with a strong hybridization signal to each receptor cDNA fragment were subcloned into the pUC18 or pcDNA3 vectors. After screening of these sublibraries based on colony hybridization using specific receptor probes, clones with 5′-

or 3'-sequences of the putative receptors were identified and isolated for DNA sequencing. As needed, the procedure was repeated up to three times to generate cDNAs encoding the complete ORF of each putative receptor for sequence analysis and for the expression of receptor proteins in eukaryotic cells. The entire coding sequences of each gene were also amplified with specific primers flanking the entire ORF in independent experiments. At least three independent PCR clones were sequenced to verify the authenticity of coding sequences. The nucleotide sequence of LGR4, as well as the amino acid sequence of the product encoded by the ORF thereof, is provided in Fig. 1. The nucleotide sequence of LGR5, as well as the amino acid sequence of the product encoded by the ORF thereof, is provided in Fig. 2.

Example 2. Comparison of deduced amino acid sequence of LGR4 and 5 cDNAs and those encoding FSH and LH receptors.

Sequence alignment of LGR4 and LGR5 with known human glycoprotein hormone receptors was performed and the results are shown in Fig. 6. Shaded residues are identical in at least two of the four receptor proteins shown.

Example 3. Expression pattern of LGR4 and 5 mRNA transcripts in different tissues.

For northern blot analysis, poly (A)+-selected RNA from different human tissues was hybridized with a ^{32}P-labeled cDNA probes. After washing, the blots were exposed to X-ray films at -70C for five days. Subsequent hybridization with a beta-actin cDNA probe was performed to estimate nucleic acid loading (8 h exposure). LGR4 was shown to be expressed in placenta, ovary, testis, adrenal, spinal cord, thyroid, stomach, trachea, heart, pancreas, kidney, prostate and spleen while LGR5 was shown to be expressed in the skeletal muscle, placenta, spinal cord, brain, adrenal, colon, stomach, ovary and bone marrow.

Example 4. Chromosomal localization of LGR4 and 5 in human.

Using genomic fragments of LGR4 (~100 Kb) and LGR5 (>100 Kb) as probes, chromosomal localization of these genes were detected using the FISH method to banded DNA in chromosomal 5q34-35.1 and 12q15, respectively.

Example 5. Identification of LGR7.

Analysis of EST databases has revealed a novel LGR closely related to a G protein-coupled receptor from pond snail (Lymnaea stagnalis, accession no. 481946). Because the snail G-protein coupled receptor shared the leucine-rich repeat ectodomain and seven transmembrane region characteristics of mammalian LGRs, the novel EST sequence could encode either a homologue of snail receptor or a novel mammalian LGR. For the isolation of LGR7 cDNA, a Clontech Marathon-ready testis cDNA pool was used as the template for 5′ and 3′ RACE with adapter and gene-specific primers. Sequence analysis of the RACE products showed that LGR7 gene encode at least two splicing variants differ at the N-terminus. The nucleotide sequence of the long variant, as well as the amino acid sequence of the product encoded by the ORF thereof, is provided in Fig. 3; while the nucleotide sequence of the short variant, as well as the amino acid sequence of the ORF thereof, is provided in Fig. 4. Both variants contain a classical C-terminal 7-transmembrane region and a leucine-rich repeat ectodomain flanked by cysteine rich regions found in other mammalian LGRs. The long form LGR7 contains extra 35 amino acids in the N-terminal cysteine rich region as compared to the short form LGR7. Of interest, analysis of the LGR7 ORF from either variant showed that its tertiary structure resembles that of mammalian LGRs instead of the snail receptor, which shares the greatest identity in the transmembrane region. These findings suggest that LGR7 and snail receptor diverged early during evolution and LGR7 perhaps adopted new function in higher organisms.

Based on the LGR7 cDNA sequence, we further identified a human genomic DNA fragment (AQ053279) in the genomic survey sequence division of GenBank that contains part of the LGR7 gene. The authenticity of this genomic clone was confirmed by Southern blot hybridization and the genomic clone was used as the probe to identify the chromosomal localization for LGR7 gene.

It is evident from the above discussion and results that three novel mammalian G-protein coupled receptors, as well as a nucleic acids encoding the same, are provided by the subject invention. The inventions described above find use in a variety of applications, including research and therapeutic applications.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such a disclosure by virtue of prior invention.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid encoding a mammalian protein selected from the group consisting of LGR4, LGR5 or LGR7.

2. An isolated nucleic acid according to Claim 1, wherein said mammalian protein has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:04, SEQ ID NO:06 or SEQ ID NO:08.

3. An isolated nucleic acid according to Claim 1, wherein said mammalian protein has an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:04, SEQ ID NO:06 or SEQ ID NO:08.

4. An isolated nucleic acid according to Claim 1, wherein the nucleotide sequence of said nucleic acid has the sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

5. An isolated nucleic acid comprising at least 18 contiguous nucleotides of the sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

6. An isolated nucleic acid comprising at least 50 contiguous nucleotides of the sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

7. An isolated nucleic acid that hybridizes under stringent conditions to a nucleic acid having the nucleotide sequence selected from the group consisting of: (a) SEQ ID NO:1 or the complementary sequence thereof; (b) SEQ ID NO:03 or the complementary sequence thereof; (c) SEQ ID NO:05 or the complementary sequence thereof; and (d) SEQ ID NO:07 or the complementary sequence thereof.

8. An expression cassette comprising a transcriptional initiation region functional in an expression host, a nucleic acid having a sequence of the isolated nucleic acid according to Claim 1 under the transcriptional regulation of said transcriptional initiation region, and a transcriptional termination region functional in said expression host.

9. A cell comprising an expression cassette according to Claim 8 as part of an extrachromosomal element or integrated into the genome of a host cell as a result of introduction of said expression cassette into said host cell, and the cellular progeny of said host cell.

10. A method for producing a mammalian protein selected from the group consisting of LGR4, LGR5 and LGR7, said method comprising:

growing a cell according to Claim 9, whereby said mammalian protein is expressed; and

isolating said protein substantially free of other proteins.

11. A purified polypeptide composition comprising at least 50 weight % of the protein present as a mammalian protein selected from the group consisting of LGR4, LGR5 and LGR7, or a fragment thereof.

12. An antibody binding specifically to a mammalian protein selected from the group consisting of LGR4, LGR5 and LGR7.

13. The antibody of Claim 12, wherein said antibody is a monoclonal antibody.

14. A non-human transgenic animal model for *LGR4*, *LGR5* or *LGR7* gene function, wherein said transgenic animal comprises an introduced alteration in an *LGR4*, *LGR5* or *LGR7* gene.

15. The animal model of claim 14, wherein said animal is heterozygous for said introduced alteration.

16. The animal model of claim 14, wherein said animal is homozygous for said introduced alteration.

17. The animal model of claim 14, wherein said introduced alteration is a knockout of endogenous *LGR4*, *LGR5* or *LGR7* gene expression.

18. A method of screening a sample for the presence of a ligand for a receptor selected from the group consisting of LGR4, LGR5 and LGR7, said method comprising:

contacting said sample with a receptor selected from the group consisting of LGR4, LGR5 and LGR7or a mimetic thereof, and

detecting the presence of a binding event between said receptor and ligand in said sample.

>LGR4 nucleotide sequence (SEQ ID NO:01)

ATGCCGGGTCCGCTTAGGCTGCTGCTGCTTCTTGCGCCTGGGGCTGCTGCTCTCGGGCCAGTGGTGCGGCGCGGCCT
CTGCTGCGCGAGGCCTGCAGCTGCGACGGCAAGGGCTCGGTGGACTGCTCCGGAAAGGGCTTGACGGCGTACCGGACGGT
CTGAGCGCTTTCACCGAAGCACTGGATATCAGTATGAACAATATCACCCAGTTACCAGAAGATGTATTTAAGAGTTTCTCA
TTTCTAGAGGAGCTACAACTGGCTGGTAACCACCTTTCTCTTATCCATCCAAAGCCTTGTCTGGGCTGAAAGAACTCAAA
CTCCTAACACTTCAGAATAATCAGTTGAGAACAGTGCTCAGTGAAGCCATTGAACGACTGAGTGCTTTGCAGTCTTTACGC
TTAGATGCCAACCATATTACCTCAGTCCCGGAGCACACTTTTGAAGGCTTGTACAGTTACGCCATCTGTGGCTGGATGAC
AACAGCTTGACGGAAGTGCCCGTGCGTCCCCTCAGCAACCTGCCAACCCTGCAGGCGCTGACCTTGGCTCTCAACAACAIC
TCAAGCATCCCTGACTTCGCTTTCACCAACCTTTCAAGCTTGGTGGTTCTGCATCTGCATAACAATAAAATTAAAAGCCTC
AGTCAACACTGTTTTGATGGACTAGATAACCTGGAAACCTTGGACTTGAATTACAATTACTTGGATGAGTTTCCTCAGGCT
ATTAAAGCCCTTCCCAGCCTTAAAGAGCTGGGATTTCACAGTAATTCTATTTCTGTTATTCCTGATGAGCATTTGGTGGT
AATCCACTGCTAAGAACTATTCATTTCTATCATAATCCTCTGTCTTTTGTGGGAACTCAGCATTTCACAACCTGTCTGAT
CTGCATTGCTTAGTCATTCGTGGTGCAAGCCTGGTGCAGTGGTTCCCCAATCTGACCGGAACTGTCCATTTGGAGAGTCTA
ACCTTGACAGGGACAAAAATAAGCAGCATACCTGATGATCTGTGCCAAAACCAAAAGATGCTGAGGACTCTGGACTTATCT
TATAACAATATAAGAGACCTTCCAAGTTTTAATGGTTCTCGTGCATTGGAAGAAATTTCATTGCAGCCTAATCAAATCTCC
CTAATAAAGGAAAATACTTTTCAAGGCCTAACATCTCTAAGGATTCTAGATCTGAGTAGAAACCTGATTCGTGAAATTCAC
AGTGGAGCTTTTGCGAAGCTTGGGACAATTACTAACCTGGATGTAAGTTTCAATGAATTAACTTCATTTCCTACGGAAGGC
CTAAATGGGCTCAATCAACTAAAGCTTGTGGGTAACTTCAAGCTGAAAGACGCCTTGGCAGCCAGAGACTTTGCTAATCTC
AGGTCTCTATCAGTACCATATGCTTATCAGTCTTGTGCATTTTGGGGGTGTGACTCTTTATGCAAATTAAACACAGAAGAT
AACAGCGCCCAAGAACACAGTGTGACAAAAAGAGAAAGGTGCTACAGATGCAGCAAATGTCACCAGCACTGCTGAGAACGAA
GAACATAGCCAAATAATTATCCACTGTACACCTTCAACAGGTGCTTTCAAGCCCTGTGAATATTTACTGGAAGCTGGATG
ATTCGCCTTACAGTGTGGTTCATTTTCCTGGTCGCCTTGCTTTTCAACCTGCTTGTCATTTTAACAGTGTTTGCGTCTTGT
TCATCACTGCCTGCCTCCAAACTCTTCATAGGCTTGATTTCTGTGTCTAACTTACTCATGGGCATCTATACTGGCATCCTT
ACTTTTCTTGATGCTGTGTCCTGGGGCGATTTGCCGAATTTGGCATTTGGTGGGAAACTGGCAGCGGCTGCAAGGTAGCC
GGGTCTCTGGCAGTCTTCTCCTCAGAGAGCGCTGTATTCCTATTAACACTGGCAGCTGTGGAAAGAAGCGTATTTGCAAAG
GATTTGATGAAACACGGGAAGAGCACTCACCTCAGACAGTTCCAGGTGGCGCCCTCTTAGCTTTGCTGGTGCCGCAGTG
GCAGGCTGCTTCCCCTTTTCCACGGAGGGCAATATTCTGCATCGCCCTTGTGTTTGCGGTTTCCTACAGGAGAAACCCCA
TCGTTAGGATTCACTGTGACCTTAGTGCTATTAAACTCACTGGCATTTTTACTAATGGCCATTATCTACACTAAACTATAC
TGCAACTTAGAGAAGGAGGACCTGTCGGAAAACTCCCAGTCTAGCGTGATTAAGCACGTTGCCTGGCTCATCTTCACAAAC
TGCATCTTCTTCTGCCCGTTGCATTTTTCTCATTTGCACCATTGATCACGGCAATGTCCATCAGCCCCGAGATAATGAAG
TCTGTTACACTGATATTCTTCCCGTTGCCTGCTTGCCTGAATCCGGTCCTGTATGTTTTCTTCAACCCAAAGTTTAAAGAA
GACTGGAAGCTACTGAAGCGGCGTGTTACCAGGAAACACGGATCTGTTTCAGTTTCCATCAGCAGCCAAGGCGGTTGTGGG
GAACAGGATTTCTACTATGACTGTGGCATGTATTCCCACTTGCAGGGTAACCTGACTGTCTCTGACTGCTGTGAGTCATTT
CTTTTGACAAAACCAGTATCATGCAAACACTTAATAAAATCGCACAGTTGTCCTGTATTGACAGCGGCCTCTTGCCAGAGG
CCAGAGGCCTACTGGTCTGATTGTGGTACACACTCAGCCCATTCTGACTATGCAGATGAAGAAGATTCCTTTCTCTCAGAC
AGCTCTGACCAGGTGCAGGCCTGTGGACGAGCCTGCTTCTACCAGAGTCGTGGATTCCCTCTGGTGCCCTATGCTTACAAT
CTACAGAGACTCAGAGACTGA

>LGR4 amino acid sequence (SEQ ID NO:02)

MPGPLGLLCFLALGLLGSAGPSGAAPPLCAAPCSCDGDRRVDCSGKGLTAVPEGLSAFTQALDISMNNITQLPEDAFKSFP
FLEELQLAGNDLSLIHPKALSGLRELKVLTLQNNQLRTVPSEAIRGLSALQSLRLDANHITSVPEDSFEGLVQLRHLWLDD
NSLTEVFVPPLSNLPTLQALTLALNNISSIPDFAFTNLSSLVVLHLHNNKIKSLSQHCFDGLDNLETLDLNYNYLDEFPQA
IKALPSLRELGFHSNSISVIPDGAFGGNPLLRPIHLYDNPLSFVGNSAFHNLSDLHCLVIRGASLVQWFPNLTGTVHLESL
TLTGTKISSIPDDLCQNQKMLKTLDLSYNNIRDLPSFNGCRALEEISLQRNQISLIKENTFQGLTSLRILDLSRNLIREIH
SGAFAKLGTITNLDVSFNELTSFPTEDLNGLNQLKLVGNFKLKDALAARDFANLRSLSVPYAYDCCAFWGCDSLCKLNTEI
NSPQEHSVTKEKGATDAANVTSTAENEEHSQIIIHCTPSTGAFKPCEYLLGSWMIFLTVWFIFLVALLFNLLVILTVFASC
SSLPASHLFIGLISVSNLLMGIYTGILTFLDAVSWGFAEFGIWWETGSGCKVAGSLAVFSSESAVFLLTLAAVERSVFAI
DLMKHGKSSHLPQFQVAALLALLGAAVAGCFFLFHGGQYSASFLCLPFPTGETPSLGFTVTLVLLNSLAFLLMAIIYTKLY
CNLEKEDLSENSQSSVIKHVAWLIFTNCIFFCFVAFFSFAPLITAISISPEIMKSVTLIFFPLPACLNPVLYVFFNPKFRE
DWKLLKRRVTRKHGSVSVSISSQGGCGEQDFYYDCGMYSHLQGNLTVCDCCESFLLTKPVSCKHLIKCHSCPVLTAASCQR
PEAYWSDCGTQSAHSDYADEEDSFVSDSSDQVQACGRACFYQSPGFPLVRYAYNLQRVFD

FIG. 1

>Nucleotide sequence of LGR5 (total 2082 nucleotides) (SEQ ID NO:03)

CTACATCTCCATAACAATAGAATCCACTCCCTGGGAAAGAAATGCTTTGATGGGCTCCACAGCCTAGAGACTTTAGATTTA
AATTACAATAACCTTGATGAATTCCCCACTGCAATTAGGACACTCTCCAACTTAAAGGAACTAGGATTTCATAGCAACAAT
ATCAGGTCGATACCTGAGAAAGCATTTGTAGGCAACCCTTCTCTTATTACAATACATTTCTATGACAATCCCATCCAATTT
GTTGGGAGATCTGCTTTTCAACATTTACCTGAACTAAGAACACTGACTCTGAATGGTGCCTCACAAATAACTGAATTTCCT
GATTTAACTGGAACTGCAAACCTGGAGAGTCTGACTTTAACTGGAGCACAGATCTCATCTCTTCCTCAAACCGTCTGCAAT
CAGTTACCTAATCTCCAAGTGCTAGATCTGTCTTACAACCTATTAGAAGATTTACCCAGTTTTTCAGTCTGCCAAAAGCTT
CAGAAAATTGACCTAAGACATAATGAAATCTACGAAATTAAAGTTGACACTTTCCAGCAGTTGCTTAGCCTCCGATCGCTG
AATTTGGCTTGGAACAAAATTGCTATTATTCACCCCAATGCATTTTCCACTTTGCCATCCCTAATAAAGCTGGACCTATCG
TCCAACCTCCTGTCGTCTTTTCCTATAACTGGGTTACATGGTTTAACTCACTTAAAATTAACAGGAAATCATGCCTTACAG
AGCTGGATATCATCTGAAAACTTTCCAGAACTCAAGGTXATAGAAATGCCTTATGCTTACCAGTGCTGTGCATTTGGAGTG
TGTGAGAATGCCTATAAGATTTCTAATCAATGGAATAAAGGTGACAACAGCAGTATGGACGACCTTCATAAGAAAGATGCT
GGAATGTTTCAGGCTCAAGATGAACGTGACCTTGAAGATTTCCTGCTTGACTTTGAGGAAGACCTGAAAGCCCTTCATTCA
GTGCAGTGTTCACCTTCCCCAGGCCCCTTCAAACCCTGTGAACACCTGCTTGATGGCTGGCTGATCAGAATTGGAGTGTGG
ACCATAGCAGTTCTGGCACTTACTTGTAATGCTTTGGTGACTTCAACAGTTTTCAGATCCCCTCTGTACATTTCCCCCATT
AAACTCTTAATTGGGGTCATCGCAGCAGTGAACATGCTCACGGGAGTCTCCAGTGCCGTGCTGGCTGGTGTGGATGCGTTC
ACTTTTGGCAGCTTTGCACGACATGGTGCCTGGTGGGAGAATGGGGTTGGTTGCCATGTCATTGGTTTTTTGTCCATTTTT
GCTTCAGAATCATCTGTTTTCCTGCTTACTCTGGCAGCCCTGGAGCGTGGGTTCTCTGTGAAATATTCTGCAAAATTTGAA
ACGAAAGCTCCATTTTCTAGCCTGAAAGTAATCATTTTGCTCTGTGCCCTGCTGGCCTTGACCATGGCCGCAGTTCCCCTG
CTGGGTGGCAGCAAGTATGGCGCCTCCCCTCTCTGCCTGCCTTTGCCTTTTGGGGAGCCCAGCACCATGGGCTACATGGTC
GCTCTCATCTTGCTCAATTCCCTTTGCTTCCTCATGATGACCATTGCCTACACCAAGCTCTACTGCAATTTGGACAAGGGA
GACCTGGAGAATATTTGGGACTGCTCTATGGTAAAACACATTGCCCTGTTGCTCTTCACCAACTGCATCCTAAACTGCCCT
GTGGCTTTCTTGTCCTTCTCCTCTTTAATAAACCTTACATTTATCAGTCCTGAAGTAATTAAGTTTATCCTTCTGGTGGTA
GTCCCACTTCCTGCATGTCTCAATCCCCTTCTCTACATCTTGTTCAATCCTCACTTTAAGGAGGATCTGGTGAGCCTGAGA
AAGCAAACCTACGTCTGGACAAGATCAAAACACCCAAGCTTGATGTCAATTAACTCTGATGATGTCGAAAAACAGTCCTGT
GACTCAACTCAAGCCTTGGTAACCTTTACCAGCTCCAGCATCACTTATGACCTGCCTCCCAGTTCCGTGCCATCACCAGCT
TATCCAGTGACTGAGAGCTGCCATCTTTCCTCTGTGGCATTTGTCCCATGTCTCTAA

>amino acid sequence of LGR5 (total 693 amino acids) (SEQ ID NO:04)

LHLHNNRIHSLGKKCFDGLHSLETLDLNYNNLDEFPTAIRTLSNLKELGFHSNNIRSIPEKAFVGNPSLITIHFYDNPIQF
VGRSAFQHLPELRTLTLNGASQITEFPDLTGTANLESLTLTGAQISSLPQTVCNQLPNLQVLDLSYNLLEDLPSFSVCQKL
QKIDLRHNEIYEIKVDTFQQLLSLRSLNLAWNKIAIIHPNAFSTLPSLIKLDLSSNLLSSFPITGLHGLTHLKLTGNHALQ
SWISSENFPELKVIEMPYAYQCCAFGVCENAYKISNQWNKGDNSSMDDLHKKDAGMFQAQDERDLEDFLLDFEEDLKALHS
VQCSPSPGPFKPCEHLLDGWLIRIGVWTIAVLALTCNALVTSTVFRSPLYISPIKLLIGVIAAVNMLTGVSSAVLAGVDAF
TFGSFARHGAWWENGVGCHVIGFLSIFASESSVFLLTLAALERGFSVKYSAKFETKAPFSSLKVIILLCALLALTMAAVPL
LGGSKYGASPLCLPLPFGEPSTMGYMVALILLNSLCFLMMTIAYTKLYCNLDKGDLENIWDCSMVKHIALLLFTNCILNCP
VAFLSFSSLINLTFISPEVIKFILLVVVPLPACLNPLLYILFNPHFKEDLVSLRKQTYVWTRSKHPSLMSINSDDVEKQSC
DSTQALVTFTSSSITYDLPPSSVPSPAYPVTESCHLSSVAFVPCL

FIG. 2

>Final LGR7 (LGR7-Long variant) full length sequence (2467 nt) (SEQ ID NO:05).

GAAAGGAGGAAAGAAAAAAAGAGGAATGGAAAGAGACAGAGAAAGGAAATGGGACTGGAAGGAGGGAGGACTGCTTT
GTAACTGCTAAGATTGCAGACAGAAATAGCACACAACCACTGTGAGCTGTATGCGATTCAGAAACCAAGACCAAATT
TTGCTCACTTTCATTAATCAGTTGCTCAGATAGAAGGAA**ATG**ACATCTGGTTCTGTCTTCTTCTACATCTTAATTTT
TGGAAAATATTTTTCTCATGGGGGTGGACAGGATGTCAAGTGCTCCCTTGGCTATTTCCCCTGTGGGAACATCACAA
AGTGCTTGCCTCAGCTCCTGCACTGTAACGGTGTGGACGACTGCGGGAATCAGGCCGATGAGGACAACTGTGGAGAC
AACAATGGATGGTCCATGCAATTTGACAAATATTTTGCCAGTTACTACAAAATGACTTCCCAATATCCTTTTGAGGC
AGAAACACCTGAATGTTTGGTCGGTTCTGTGCCAGTGCAATGTCTTTGCCAAGGTCTGGAGCTTGACTGTGATGAAA
CCAATTTACGAGCTGTTCCATCGGTTTCTTCAAATGTGACTGCAATGTCACTTCAGTGGAACTTAATAAGAAAGCTT
CCTCCTGATTGCTTCAAGAATTATCATGATCTTCAGAAGCTGTACCTGCAAAACAATAAGATTACATCCATCTCCAT
CTATGCTTTCAGAGGACTGAATAGCCTTACTAAACTGTATCTCAGTCATAACAGAATAACCTTCCTGAAGCCGGGTG
TTTTTGAAGATCTTCACAGACTAGAATGGCTGATAATTGAAGATAATCACCTCAGTCGAATTTCCCCACCAACATTT
TATGGACTAAATTCTCTTATTCTCTTAGTCCTGATGAATAACGTCCTCACCCGTTTACCTGATAAACCTCTCTGTCA
ACACATGCCAAGACTACATTGGCTGGACCTTGAAGGCAACCATATCCATAATTTAAGAAATTTGACTTTTATTTCCT
GCAGTAATTTAACTGTTTTAGTGATGAGGAAAAACAAAATTAATCACTTAAATGAAAATACTTTTGCACCTCTCCAG
AAACTGGATGAATTGGATTTAGGAAGTAATAAGATTGAAAATCTTCCACCGCTTATATTCAAGGACCTGAAGGAGCT
GTCACAATTGAATCTTTCCTATAATCCAATCCAGAAAATTCAAGCAAACCAATTTGATTATCTTGTCAAACTCAAGT
CTCTCAGCCTAGAAGGGATTGAAATTTCAAATATCCAACAAAGGATGTTTAGACCTCTTATGAATCTCTCTCACATA
TATTTTAAGAAATTCCAGTACTGTGGGTATGCACCACATGTTCGCAGCTGTAAACCAAACACTGATGGAATTTCATC
TCTAGAGAATCTCTTGGCAAGCATTATTCAGAGAGTATTTGTCTGGGTTGTATCTGCAGTTACCTGCTTTGGAAACA
TTTTTGTCATTTGCATGCGACCTTATATCAGGTCTGAGAACAAGCTGTATGCCATGTCAATCATTTCTCTCTGCTGT
GCCGACTGCTTAATGGGAATATATTTATTCGTGATCGGAGGCTTTGACCTAAAGTTTCGTGGAGAATACAATAAGCA
TGCGCAGCTGTGGATGGAGAGTACTCATTGTCAGCTTGTAGGATCTTTGGCCATTCTGTCCACAGAAGTATCAGTTT
TACTGTTAACATTTCTGACATTGGAAAAATACATCTGCATTGTCTATCCTTTTAGATGTGTGAGACCTGGAAAATGC
AGAACAATTACAGTTCTGATTCTCATTTGGATTACTGGTTTTATAGTGGCTTTCATTCCATTGAGCAATAAGGAATT
TTTCAAAAACTACTATGGCACCAATGGAGTATGCTTCCCTCTTCATTCAGAAGATACAGAAAGTATTGGAGCCCAGA
TTTATTCAGTGGCAATTTTTCTTGGTATTAATTTGGCCGCATTTATCATCATAGTTTTTTCCTATGGAAGCATGTTT
TATAGTGTTCATCAAAGTGCCATAACAGCAACTGAAATACGGAATCAAGTTAAAAAAGAGATGATCCTTGCCAAACG
TTTTTTCTTTATAGTATTTACTGATGCATTATGCTGGATACCCATTTTTGTAGTGAAATTTCTTTCACTGCTTCAGG
TAGAAATACCAGGTACCATAACCTCTTGGGTAGTGATTTTTATTCTGCCCATTAACAGTGCTTTGAACCCAATTCTC
TATACTCTGACCACAAGACCATTTAAAGAAATGATTCATCGGTTTTGGTATAACTACAGACAAAGAAAATCTATGGA
CAGCAAAGGTCAGAAAACATATGCTCCATCATTCATCTGGGTGGAAATGTGGCCACTGCAGGAGATGCCACCTGAGT
TAATGAAGCCGGACCTTTTCACATACCCCTGTGAAATGTCACTGATTTCTCAATCAACGAGACTCAATTCCTATTCA
TGA

>Final LGR7 (LGR7-long variant, total 757 amino acids)(SEQ ID NO:06)

MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADEDNCGDNNGWSMQFDKYFA
SYYKMTSQYPFEAETPECLVGSVPVQCLCQGLELDCDETNLRAVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQK
LYLQNNKITSISIYAFRGLNSLTKLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMN
NVLTRLPDKPLCQHMPRLHWLDLEGNHIHNLRNLTFISCSNLTVLVMRKNKINHLNENTFAPLQKLDELDLGSNKIE
NLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLEGIEISNIQQRMFRPLMNLSHIYFKKFQYCGYAPH
VRSCKPNTDGISSLENLLASIIQRVFVWVVSAVTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIG
GFDLKFRGEYNKHAQLWMESTHCQLVGSLAILSTEVSVLLLTFLTLEKYICIVYPFRCVRPGKCRTITVLILIWITG
FIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIIVFSYGSMFYSVHQSAITATEI
RNQVKKEMILAKRFFFIVFTDALCWIPIFVVKFLSLLQVEIPGTITSWVVIFILPINSALNPILYTLTTRPFKEMIH
RFWYNYRQRKSMDSKGQKTYAPSFIWVEMWPLQEMPPELMKPDLFTYPCEMSLISQSTRLNSYS*

FIG. 3

>Final LGR7 (LGR7-Short variant) full length sequence (3584 nt)(SEQ ID NO:07)

CTGCTTTGTAACTGCTAAGATTGCAGACAGAAATAGCACACAACCACTGTGAGCTGTATGCGATTCAGAAACCAAGA
CCAAATTTTGCTCACTTTCATTAATCAGTTGCTCAGATAGAAGGAA**ATG**ACATCTGGTTCTGTCTTCTTCTACATCT
TAATTTTTGGAAAATATTTTTCTCATGGGGGTGGACAGGATGTCAAGTGCTCCCTTGGCTATTTCCCCTGTGGGAAC
ATCACAAAGTGCTTGCCTCAGCTCCTGCACTGTAACGGTGTGGACGACTGCGGAATCAGGCCGATGAGGACAACTG
TGTGGTGGTTTTGTGCCAGTGCATGTCTTTGCCAGGTCTGGAGCTTGACTGGATGAAACCATTTACGAGTGTTCCAT
CGGTTTCTTCAAATGTGACTGCAATGTCACTTCAGTGGAACTTAATAAGAAAGCTTCCTCCTGATTGCTTCAAGAAT
TATCATGATCTTCAGAAGCTGGACCTGCAAAACAATAAGATTACATCCATCTTCATCTATGCTTTCAGAGGACTGAA
TAGCCTTACTAAACTGTATCTCAGTCATAACAGAATAACCTTCCTGAAGCCGGGTGTTTTTGAAGATCTTCACAGAC
TAGAATGGCTGATAATTGAAGATAATCACCTCAGTCGAATTTCCCCACCAACATTTTATGGACTAAATTCTCTTATT
CTCTTAGTCCTGATGAATAACGTCCTCACCCGTTTACCTGATAAACCTCTCTGTCAACACATGCCAAGACTACATTG
GCTGGACCTTGAAGGCAACCATATCCATAATTTAAGAAATTTGACTTTTATTTCCTGCAGTAATTTAACTGTTTTAG
TGATGAGGAAAAACAAAATTAATCACTTAAATGAAAATACTTTTGCACCTCTCCAGAAACTGGATGAATTGGATTTA
GGAAGTAATAAGATTGAAAATCTTCCACCGCTTATATTCAAGGACCTGAAGGAGCTGTCACAATTGAATCTTTCCTA
TAATCCAATCCAGAAAATTCAAGCAAACCAATTTGATTATCTTGTCAAACTCAAGTCTCTCAGCCTAGAAGGGATTG
AAATTTCAAATATCCAACAAAGGATGTTTAGACCTCTTATGAATCTCTCTCACATATATTTTAAGAAATTCCAGTAC
TGTGGGTATGCACCACATGTTCGCAGCTGTAAACCAAACACTGATGGAATTTCATCTCTAGAGAATCTCTTGGCAAG
CATTATTCAGAGAGTATTTGTCTGGGTTGTATCTGCAGTTACCTGCTTTGGAAACATTTTTGTCATTTGCATGCGAC
CTTATATCAGGTCTGAGAACAAGCTGTATGCCATGTCAATCATTTCTCTCTGCTGTGCCGACTGCTTAATGGGAATA
TATTTATTCGTGATCGGAGGCTTTGACCTAAAGTTTCGTGGAGAATACAATAAGCATGCGCAGCTGTGGATGGAGAG
TACTCATTGTCAGCTTGTAGGATCTTTGGCCATTCTGTCCACAGAAGTATCAGTTTTACTGTTAACATTTCTGACAT
TGGAAAAATACATCTGCATTGTCTATCCTTTTAGATGTGTGAGACCTGGAAAATGCAGAACAATTACAGTTCTGATT
CTCATTTGGATTACTGGTTTTATAGTGGCTTTCATTCCATTGAGCAATAAGGAATTTTTCAAAAACTACTATGGCAC
CAATGGAGTATGCTTCCCTCTTCATTCAGAAGATACAGAAAGTATTGGAGCCCAGATTTATTCAGTGGCAATTTTTC
TTGGTATTAATTTGGCCGCATTTATCATCATAGTTTTTTCCTATGGAAGCATGTTTTATAGTGTTCATCAAAGTGCC
ATAACAGCAACTGAAATACGGAATCAAGTTAAAAAAGAGATGATCCTTGCCAAACGTTTTTTCTTTATAGTATTTAC
TGATGCATTATGCTGGATACCCATTTTTGTAGTGAAATTTCTTTCACTGCTTCAGGTAGAAATACCAGGTACCATAA
CCTCTTTGGGTAGTGATTTTTATTCTGCCCATTAACAGTGCTTTGAACCCAATTCTCTATACTCTGACCACAAGACCA
TTTAAAGAAATGATTCATCGGTTTTGGTATAACTACAGACAAAGAAAATCTATGGACAGCAAAGGTCAGAAAACATA
TGCTCCATCATTCATCTGGGTGGAAATGTGGCCACTGCAGGAGATGCCACCTGAGTTAATGAAGCCGGACCTTTTCA
CATACCCCTGTGAAATGTCACTGATTTCTCAATCAACGAGACTCAATTCCTATTCA**TGA**CTGACTCTGAAATTCATT
TCTTCGCAGAGAATACTGTGGGGGTGCTTCATGAGGGATTTACTGGTATGAAAATGAATACCACAAAATTAATTTAT
AATAATAGCTAAGATAAATATTTTACAAGGACATGAGGAAAAATAAAAATGACTAATGCTCTTACAAAGGGAAGTAA
TTATATCAATAATGTATATATATTAGTAGACATTTTGCATAAGAAATTAAGAGAAATCTACTTCAGTAACATTCATT
CATTTTTCTAACATGCATTTATTGAGTACCCACTACTATGTGCATAGCATTGCAATATAGTCCTGGAAGTAGACAGT
GCAGAACCTTTCAATCTGTAGATAGTGTTTAATGACAAAAGACTATACAAAGTCCATCTGCAGTTCCTAGTTTAAAG
TAGAGCTTTACCTGTCATGTGCATCAGCAAGAATCATAGGCACTTTTAAATAAAGGTTTAAAGTTTTGGAATACTCA
GTGTATTTGCATCATAGAAAATGTCTGACTGTTTGCAAAATAATATTCTGTTTTAAGAATCCATCTTACCTCTCTTT
AAGTTTCCATACACTTGAGAGCCAACACAACATATTTATTACTAAAAAGATGCTTTGCTAGAAACTCAAAAACAGCA
CTTCTTTTGGCACTTCCTGCCCAGTTTTCTCTTTGCTTTAAATGAACATCATCATATGGAATTGGAATAGGAGAGTA
TGAGTACGGCAGAGAAGTGGATCAGAAAAACTAGAATGAGGATAAACATTTACATTAGTGGAAACTCCTGAAATAAA
TCCTTGTATTGTCAGTTAACTGATTTTCAACAAGGATGCCAAGACAAAAAGGCTTTTCAACAAACCGTGCTGTTTTA
AGAACAGACCTAAGTGGTTTAATTCACCCACTTTAGATGGGTGAATGTTATGGTGTGTGAAATATCTCAGTAAAGCA
GTTAAAAGGAAAAAGAGCTGGAATGCACTGATTCAGGAACTTAATTTCAGGAAGGAAAGGTCTGTATGTACACATTT
CACTTTAAGCAGAAAATCTTTCTTCAAGAAATGACTTTACTTTCTCTTTGCACTGCCAGCACGTGAGATACTAACTT
TTTAACTAGTTGTTCTTCTCTAGTCTCTACGTTATTAGNATTTTTTGCTTTCATAATGTGAAACCTTTAAGCAGGAG
AAGAAAATGTTTTCAGATAGTTTCAAATACNCCAAAAATGTTTGCAACACAAAAATACTGGAATCNAACCATAATGC
CCTTATTGAATATATAGTTGTATAGNTTTGTTCTGAAAACCC

>Final LGR7-S ORF (722 amino acids) (SEQ ID NO:08)

MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADEDNCVVVLCQRMSLPGLEL
DWMKPFTSVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLDLQNNKITSISIYAFRGLNSLTKLYLSHNRITFL
KPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMNNVLTRLPDKPLCQHMPRLHWLDLEGNHIHNLRNLT
FISCSNLTVLVMRKNKINHLNENTFAPLQKLDELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLV
KLKSLSLEGIEISNIQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCKPNTDGISSLENLLASIIQRVFVWVVSAVTC
FGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGGFDLKFRGEYNKHAQLWMESTHCQLVGSLAILSTE
VSVLLLTFLTLEKYICIVYPFRCVRPGKCRTITVLILIWITGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESI
GAQIYSVAIFLGINLAAFIIIVFSYGSMFYSVHQSAITATEIRNQVKKEMILAKRFFFIVFTDALCWIPIFVVKFLS
LLQVEIPGTITSWVVIFILPINSALNPILYTLTTRPFKEMIHRFWYNYRQRKSMDSKGQKTYAPSFIWVEMWPLQEM
PPELMKPDLFTYPCEMSLISQSTRLNSYS*

FIG. 4

>Alignment of LGR7-L with LGR7-S

Query=LGR7-L

Sbjct=LGR7-S

```
Query: 1   MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADED 60
           MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADED
Sbjct: 1   MTSGSVFFYILIFGKYFSHGGGQDVKCSLGYFPCGNITKCLPQLLHCNGVDDCGNQADED 60

Query: 61  NCGDNNGWSMQFDKYFASYYKMTSQYPFEAETPECLVGSVPVQCLCQ---GLELDCDETN 117
           NC                                      V V C C    GLELD  +
Sbjct: 61  NC--------------------------------------VVVLCQCMSLPGLELDWMKP- 82

Query: 118 LRAVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLYLQNNKITSISIYAFRGLNSLT 177
             +VPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKL LQNNKITSISIYAFRGLNSLT
Sbjct: 83  FTSVPSVSSNVTAMSLQWNLIRKLPPDCFKNYHDLQKLDLQNNKITSISIYAFRGLNSLT 142

Query: 178 KLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMNNVLTRL 237
           KLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMNNVLTRL
Sbjct: 143 KLYLSHNRITFLKPGVFEDLHRLEWLIIEDNHLSRISPPTFYGLNSLILLVLMNNVLTRL 202

Query: 238 PDKPLCQHMPRLHWLDLEGNHIHNLRNLTFISCSNLTVLVMRKNKINHLNENTFAPLQKL 297
           PDKPLCQHMPRLHWLDLEGNHIHNLRNLTFISCSNLTVLVMRKNKINHLNENTFAPLQKL
Sbjct: 203 PDKPLCQHMPRLHWLDLEGNHIHNLRNLTFISCSNLTVLVMRKNKINHLNENTFAPLQKL 262

Query: 298 DELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLEGIEISN 357
           DELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLEGIEISN
Sbjct: 263 DELDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSLSLEGIEISN 322

Query: 358 IQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCKPNTDGISSLENLLASIIQRVFVWVVSA 417
           IQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCKPNTDGISSLENLLASIIQRVFVWVVSA
Sbjct: 323 IQQRMFRPLMNLSHIYFKKFQYCGYAPHVRSCKPNTDGISSLENLLASIIQRVFVWVVSA 382

Query: 418 VTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGGFDLKFRGEYNKHAQ 477
           VTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGGFDLKFRGEYNKHAQ
Sbjct: 383 VTCFGNIFVICMRPYIRSENKLYAMSIISLCCADCLMGIYLFVIGGFDLKFRGEYNKHAQ 442

Query: 478 LWMESTHCQLVGSLAILSTEVSVLLLTFLTLEKYICIVYPFRCVRPGKCRTITVLILIWI 537
           LWMESTHCQLVGSLAILSTEVSVLLLTFLTLEKYICIVYPFRCVRPGKCRTITVLILIWI
Sbjct: 443 LWMESTHCQLVGSLAILSTEVSVLLLTFLTLEKYICIVYPFRCVRPGKCRTITVLILIWI 502

Query: 538 TGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIIVF 597
           TGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIIVF
Sbjct: 503 TGFIVAFIPLSNKEFFKNYYGTNGVCFPLHSEDTESIGAQIYSVAIFLGINLAAFIIIVF 562

Query: 598 SYGSMFYSVHQSAITATEIRNQVKKEMILAKRFFFIVFTDALCWIPIFVVKFLSLLQVEI 657
           SYGSMFYSVHQSAITATEIRNQVKKEMILAKRFFFIVFTDALCWIPIFVVKFLSLLQVEI
Sbjct: 563 SYGSMFYSVHQSAITATEIRNQVKKEMILAKRFFFIVFTDALCWIPIFVVKFLSLLQVEI 622

Query: 658 PGTITSWVVIFILPINSALNPILYTLTTRPFKEMIHRFWYNYRQRKSMDSKGQKTYAPSF 717
           PGTITSWVVIFILPINSALNPILYTLTTRPFKEMIHRFWYNYRQRKSMDSKGQKTYAPSF
Sbjct: 623 PGTITSWVVIFILPINSALNPILYTLTTRPFKEMIHRFWYNYRQRKSMDSKGQKTYAPSF 682

Query: 718 IWVEMWPLQEMPPELMKPDLFTYPCEMSLISQSTRLNSYS 757
           IWVEMWPLQEMPPELMKPDLFTYPCEMSLISQSTRLNSYS
Sbjct: 683 IWVEMWPLQEMPPELMKPDLFTYPCEMSLISQSTRLNSYS 722
```

FIG. 5

FIG. 6

Signal peptide

```
LGR4    MPGPLGLLCFLALGLLGSAGPSGA
LGR5    MDTSRLGVLLSLPVLLQLATG
LHR     MKQRFSALQLLKLLLLLQPPLPRA
FSHR    MALLLVSLLAFLSLGSG
TSHR    MRPADLLQLVLLLDLPRDLGG
```

N-flank cysteine-rich sequence

```
LGR4            APPL AA-P S DGDR----RVD SGKGLTAVPEGLSAFTQA
LGR5   GSSPRSGVLLRG P-TH H EPDGRMLLRVD SDLGLSELPSNLSVFTSY
LHR            LREAL P-EP N VPDG--ALR-- PGPTAGLTR
FSHR                HHRI H SNRVFL----- QESKVTEIPSDLPRNAIE
TSHR              MG SSPP E HQEED--FRVT KDIQRIPSLPPSTQT
```

Leucine-rich repeats

```
LGR4    DISMNNITQLPED  KSFPFLEELQLAGN -- SL HPKALSG KE KVLTLQ -- Q
LGR5    DLSMNNISQLLPNPLPSLHFLEELRLAGNA-- TY PKGA TG YS KVLMLQ -- Q
LHR     SLAYLPVKVIPSQ  RGLNEVIKIEISQI S- ER EANA DN LN SEILIQ TK -
FSHR    RFVLTKLRVIQKG  SGFGDLEKIEISQN V- EV EADV SN PK HEIRIEKAN -
TSHR    KLIETHLRTIPSH  SNLPNISRIYVSI- VT QQLESHS YN SKVTHIEIR TR -

LGR4    RTV- SE IHG SA QS RLDA H- TSV EDS--FEGLVQLRH WLD  S-L- EV VR
LGR5    RHV- TE LQN RS QS RLDA H- SYV P-SC-FSGLHSLRH WLD  A-L- E  VQ
LHR     RYIE -G FIN PG KY SIC- TG RKF DVTKVFSSESNFI- EIC  LHI- T  GN
FSHR    LYIN -E FQN PN QY LIS- TG KHL DVHK-IHSLQKVL- DIQ  INIH - ERN
TSHR    TYID -D LKE PL KF GIF- TGLKMF DLTK-VYSTDIFFI EIT  PYM- S  VN

LGR4    PLSN P-TLQA T AL NISSIPDF  T LSS VV H HN K-IKSLSQHC D LDN-LE
LGR5    A RS S-ALQAMT AL KIHHIPDY  G LSSWVV H HN R-IHSLGKKC D LHS-LE
LHR     A QGMNNESVT K YG GFEEVQSH  - GTT TS E KE VHLEKMHNGA R A-TGPK
FSHR    S VG SFESVI W NK GIQEIHNC  - GTQ DE N SD NNLEELPNDV H A-SGPV
TSHR    A QG CNETLT K YN GFTSVQGY  - GTK DAVY NK KYLTVIDKDA G VYSGPS

LGR4    T  LNYNYLDEF Q-AIKA PS KELGFHSNSISVI D-GA GGNPL RTIH - DNPLS
LGR5    T  LNYNNLDEF T-AIRT SN KELGFHSNNIRSI E-KA VGNPS ITIHF- DNPIQ
LHR     T  ISSTKLQAL SYGLESIQR I-ATS-SYSLKKL SRET V-N-- LEAT T -----
FSHR    I  ISRTRIHSL SYGLEN KK R-ARSTYN-LKKL TLEKLVA--- MEAS T -----
TSHR    L  VSQTSVTAL SKGLEH KE I-ARNTWT-LKKL LSLS LH--- TRAD S -----

LGR4    FVGNSAFHNLSDLHCLVIRGASLVQWFPNLTGTVHLESLTLTGTKISSIPDDLCQNQKML
LGR5    FVGRSAFQHLPELRTLTLNGASQITEFPDLTGTANLESLTLTGAQISSLPQTVCNQLPNL
LHR     ------------------------------------------------------------
FSHR    ------------------------------------------------------------
TSHR    ------------------------------------  ----------------------
```



C-flank cysteine-rich sequence

```
LGR4   LVGNFKLKDALAARDFANLRSLSV YAYQ    WGCDSLCKLNTEDNSPQEHSVTKEKGA
LGR5   LTGNHALQSLISSENFPELKVIEM YAYQ    GVCENAYKISNQWNKGDNSSMDDLHKK
LHR    ------------------------ --SH    RNLPTKEQNFSHSISENFSKQCESTVR
FSHR   ------------------------ --SH    ANWRRQISELHPICNKSILRQEVDYMT
TSHR   ------------------------ --SH    KNQKKIRGILESLMCNESSMQSLRQRK

LGR4   TDAANVTSTAENE HS-----------------------------------------------
LGR5   DAGMFQAQDERDL DF-----------------------------------------------
LHR    KVSNKTLYSSMLA SE-----------------------------------------------
FSHR   QTRGQRSSLAEDN SS-----------------------------------------------
TSHR   SVNALNSPLHQEY ENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQEDEIIGFGQELKNP

LGR4   -------------------QIIIH T STGA K   YLLGSWMI
LGR5   ---------LLDFEEDLKALHSVQ S SPGP K   HLLDGWLI
LHR    ------LSGWDYEYGFCLPKTPR- A EPDA N   DIMGYDFL
FSHR   YSRGFDMTYTEFDYDLCNEVVDVT S KPDA N   DIMGYNIL
TSHR   QEETLQAFDSHYDYTICGDSEDMV T KSDE N   DIMGYKFL
```

Transmembrane

```
                TM 1                              TM 2
LGR4   LTV F FLV LLF LL ILTVFA CSS PASKLFIGLISVSNLLM IYTGILTFL AVSW
LGR5   IGV T AV  LTC AL TSTVFR PLYISPIKL IGVIAAVNMLT VSSAVL G  AF F
LHR    VLI L NI  IMG MT LFVLLT RYK TVPRF MCNLSFADFCM LYLLLI S  SQ K
FSHR   VLI F SI  ITG II LVILTT QYK TVPRF MCNLAFADLCI IYLLLI S  IH K
TSHR   IVV FVSL  LLG VF LLILLT HYK NVPRF MCNLAFADFCM MYLLLI S  LY H

                          TM 3                                    -
LGR4   GRFAEFG W E  S  KV  SLA  S  SA FL  LAAV  SVFAKDLMKHGKSSH  QF
LGR5   GSFARHGAW EN V  HVI  LSI     S  FL  LAA   GFSVKYSAKFET APFSSL
LHR    GQYYNHA D Q  S  ST  FT      L  YT  VIT   WHTITYAIHLDQ LR  HA
FSHR   SQYHNYA D Q  A  DA  FT      L  YT  AIT   WHTITHAMQLDC VQ  HA
TSHR   SEYYNHA D Q  P  NT  FT      L  YT  VIT   WYAITFAMRLDR IR  HA
```

FIG. 6 (CONT)

```
                    TM 4                                                    TM 5
LGR4    QVAALLALLGAAVAGCF  FHGGQ SASPL   FPTGETPSLGFTVTLVL  SL  LLMA
LGR5    KVIILLCALLALTM AV  L G K GASPL   LPFGEPSTMG MVALIL  SLC LMMT
LHR     ILIMLGGWLFSSLI ML  V V N MKVSI F MDVETTLSQV ILTILI  VV  FIIC
FSHR    ASVMVMGWIFAFAA LF IF I S MKVSI   MDIDSPLSQL VMSLLV  VL  VVIC
TSHR    CAIMVGGWVCCFLL LL  V I S AKVSI   MDTETPLALA IVFVLT  IV  VIVC

                                                    TM 6
LGR4    II T L CNL-EKEDLSENSQSSVI HV W     NCIFFC VA FSFAPLITAIS SPEI
LGR5    IA T L CNL-DKGDLENIW CSMV HI L L   NCILNC VA LSF SLIINLTF SPEV
LHR     AC I I FAVRNPELMATNK TKIA KM I     DFTCMA IS FAI AAFKVPL TVTN
FSHR    GC IHI LTVRNPNIVSSSS TRIA RM M     DFLCMA IS FAI ASLKVPL TVSK
TSHR    CCHV I ITVRNPQYNPGDK TKIA RM V     DFICMA IS YAL AILNKPL TVSN

                    TM 7
LGR4    M SVTLI F LPA L  V  VF N
LGR5    I FI LVVV LPA L  L  IL N
LHR     S VL VL Y INS A  F  AI T
FSHR    A IL VL H INS A  F  AI T
TSHR    S IL VL Y LNS A  F  AI T
```

C-terminal tail

```
LGR4    PK KE WKL KRRVTRKHGSVSVSISSQGGCGEQDFYYDCGMYSHLQGNLTVCDCCESFL
LGR5    PH KE LVS RKQTYVWTRSKHPSLMSINSDDVEKQSCDSTQALVTFTSSSITYDLPPSS
LHR     KT QR FFL LSKFGCCKRRAELYRRKDFSAYTSNCKNGFTGSNKPSQSTLKLSTLHCQG
FSHR    KN RR FFI LSKCGCYEMQAQIYRTETSSTVHNTHPRNGHCSSAPRVTNGSTYILVPLS
TSHR    KA QR VFI LSKFGICKRQAQAYRGQRVPPKNSTDIQVQKVTHDMRQGLHNMEDVYELI

LGR4    LTKPVSCKHLIKSHSCPVLTAASCQRPEAYWSDCGTQSAHSDYADEEDSFVSDSSDQVQA
LGR5    VPSPAYPVTESCHLSSVAFVPCL
LHR     TALLDKTRYTEC
FSHR    HLAQN
TSHR    ENSHLTPKKQGQISEEYMQTVL

LGR4    CGRACFYQSRGFPLVRYAYNLQRVRD
```

FIG. 6 (CONT)

SEQUENCE LISTING

<110> Hsueh, Aaron
Hsu, Yu Sheau
Liang, Chan-Guang
van der Spek, Petrus Johannes

<120> Novel Mammalian G-Protein Coupled
Receptors Having Extracellular Leucine Rich Repeat Regions

<130> SUN-84PCT

<160> 8

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 2856
<212> DNA
<213> Human

<400> 1

atgccgggcc cgctagggct gctctgcttc ctcgccctgg ggctgctcgg ctcggccggg 60
cccagcgggg cggcgccgcc tctctgcgcg gcgccctgca gctgcgacgg cgaccgtcgg 120
gtggactgct ccggaaaggg gttgacggcc gtaccggagg gtctcagcgc cttcacccaa 180
gcactggata tcagtatgaa caatatcacc cagttaccag aagatgcatt taagagtttc 240
ccatttctag aggagctaca actggctggt aacgaccttt ctcttatcca tccaaaagcc 300
ttgtctgggc tgaaagaact caaagtccta acactccaga ataatcagtt gagaacagtg 360
cccagtgaag ccattcacgg actgagtgct ttgcagtctt tacgcttaga tgccaaccat 420
attacctcag tcccggagga cagttttgaa gggcttgtcc agttacgcca tctgtggctg 480
gatgacaaca gcttgacgga agtgcccgtg cgtcccctca gcaacctgcc aaccctgcag 540
gcgctgacct tggctctcaa caacatctca agcatccctg actcgcttct caccaacctt 600
tcaagcttgg tggttctgca tctgcataac aataaaatta aaagcctcag tcaacactgt 660
tttgatggac tagataacct ggaaaccttg gacttgaatt acaattactt ggatgagttt 720
cctcaggcta ttaaagccct tcccagcctt aaagagctgg gatttcacag taattctatt 780
tctgttattc ctgatggagc atttggtggt aatccactgc taagaactat tcatttgtat 840
gataatcctc tgtctttttgt ggggaactca gcatttcaca acctgtctga tctgcattgc 900
ttggagagtc taaccttgac agggacaaaa ataagcagca tacctgatga tctgtgccaa 1020
aaccaaaaga tgctgaggac tctggactta tcttataaca atataagaga ccttccaagt 1080
tttaatggtt gtcgtgcatt ggaagaaatt tcattgcagc gtaatcaaat ctccctaata 1140
aaggaaaata cttttcaagg cctaacatct ctaaggattc tagatctgag tagaaacctg 1200
atccgtgaaa ttcacagtgg agcttttgcg aagcttggga caattactaa cctggatgta 1260
agtttcaatg aattaacttc atttcctacg gaaggcctaa atgggctcaa tcaactaaag 1320
cttgtgggta acttcaagct gaaagacgcc ttggcagcca gagactttgc taatctcagg 1380
tctctatcag taccatatgc ttatcagtgt tgtgcatttt gggggtgtga ctctttatgc 1440
aaattaaaca cagaagataa cagccccaa gaacacagtg tgacaaaaga gaaaggtgct 1500
acagatgcag caaatgtcac cagcactgct gagaacgaag aacatagcca aataattatc 1560
cactgtacac cttcaacagg tgctttcaag cctgtgaat atttactggg aagctggatg 1620
attcgcctta cagtgtggtt catttcctg gtcgccttgc ttttcaacct gcttgtcatt 1680
ttaacagtgt ttgcgtcttg ttcatcactg cctgcctcca aactcttcat aggcttgatt 1740
tctgtgtcta acttactcat gggcatctat actggcatcc ttacttttct tgatgctgtg 1800
tcctggggcc gatttgccga atttggcatt tggtgggaaa ctggcagcgg ctgcaaggta 1860
gccgggtctc tggcagtctt ctcctcagag agcgctgtat tcctattaac actggcagct 1920
gtggaaagaa gcgtatttgc aaaggatttg atgaaacacg ggaagagcag tcacctcaga 1980
cagttccagg tggccgccct cttagctttg ctgggtgccg cagtggcagg ctgcttcccc 2040
cttttccacg gagggcaata ttctgcatcg cccttgtgtt tgccgtttcc tacaggagaa 2100

[illegible] 2160
[illegible] 2220
[illegible] 2280
[illegible] 2340
[illegible] 2400
[illegible] 2460
[illegible] 2520
[illegible] 2580
[illegible] 2640
[illegible] 2700
acacagtcag cccattctca ttatgcagat gaaagaagatt ttttgtctta agacagctct 2760
gaccaggtgc aggcctatgg acagccctgc ttctaccaga gtcatggatt ccctctggtg 2820
cactatgctt acaaatctaca gagagtcaga gactga 2856

<210> 1
<211> 951
<212> PRT
<213> human

<400> 1

Met	Pro	Gly	Pro	Leu	Gly	Leu	Leu	Cys	Phe	Leu	Ala	Leu	Gly	Leu	Leu
1				5				10					15		
Gly	Ser	Ala	Gly	Pro	Ser	Gly	Ala	Ala	Pro	Pro	Leu	Cys	Ala	Ala	Pro
			20				25					30			
Cys	Ser	Cys	Asp	Gly	Asp	Arg	Arg	Val	Asp	Cys	Ser	Gly	Lys	Gly	Leu
		35					40					45			
Thr	Ala	Val	Pro	Glu	Gly	Leu	Ser	Ala	Phe	Thr	Gln	Ala	Leu	Asp	Ile
	50					55					60				
Ser	Met	Asn	Asn	Ile	Thr	Gln	Leu	Pro	Glu	Asp	Ala	Phe	Lys	Ser	Phe
65					70					75					80
Pro	Phe	Leu	Glu	Glu	Leu	Gln	Leu	Ala	Gly	Asn	Asp	Leu	Ser	Leu	Ile
				85					90					95	
His	Pro	Lys	Ala	Leu	Ser	Gly	Leu	Lys	Glu	Leu	Lys	Val	Leu	Thr	Leu
			100					105					110		
Gln	Asn	Asn	Gln	Leu	Arg	Thr	Val	Pro	Ser	Glu	Ala	Ile	His	Gly	Leu
		115					120					125			
Ser	Ala	Leu	Gln	Ser	Leu	Arg	Leu	Asp	Ala	Asn	His	Ile	Thr	Ser	Val
	130					135					140				
Pro	Glu	Asp	Ser	Phe	Glu	Gly	Leu	Val	Gln	Leu	Arg	His	Leu	Trp	Leu
145					150					155					160
Asp	Asp	Asn	Ser	Leu	Thr	Glu	Val	Pro	Val	Arg	Pro	Leu	Ser	Asn	Leu
				165					170					175	
Pro	Thr	Leu	Gln	Ala	Leu	Thr	Leu	Ala	Leu	Asn	Asn	Ile	Ser	Ser	Ile
			180					185					190		
Pro	Asp	Phe	Ala	Phe	Thr	Asn	Leu	Ser	Ser	Leu	Val	Val	Leu	His	Leu
		195					200					205			
His	Asn	Asn	Lys	Ile	Lys	Ser	Leu	Ser	Gln	His	Cys	Phe	Asp	Gly	Leu
	210					215					220				
Asp	Asn	Leu	Glu	Thr	Leu	Asp	Leu	Asn	Tyr	Asn	Tyr	Leu	Asp	Glu	Phe
225					230					235					240
Pro	Gln	Ala	Ile	Lys	Ala	Leu	Pro	Ser	Leu	Lys	Glu	Leu	Gly	Phe	His
				245					250					255	
Ser	Asn	Ser	Ile	Ser	Val	Ile	Pro	Asp	Gly	Ala	Phe	Gly	Gly	Asn	Pro
			260					265					270		
Leu	Leu	Arg	Thr	Ile	His	Leu	Tyr	Asp	Asn	Pro	Leu	Ser	Phe	Val	Gly
		275					280					285			
Asn	Ser	Ala	Phe	His	Asn	Leu	Ser	Asp	Leu	His	Cys	Leu	Val	Ile	Arg
	290					295					300				

Gly Ala Ser Leu Val Gln Trp Phe Pro Asn Leu Thr Gly Thr Val His
305 310 315 320
Leu Glu Ser Leu Thr Leu Thr Gly Thr Lys Ile Ser Ser Ile Pro Asp
325 330 335
Asp Leu Cys Gln Asn Gln Lys Met Leu Arg Thr Leu Asp Leu Ser Tyr
340 345 350
Asn Asn Ile Arg Asp Leu Pro Ser Phe Asn Gly Cys Arg Ala Leu Glu
355 360 365
Glu Ile Ser Leu Gln Arg Asn Gln Ile Ser Leu Ile Lys Glu Asn Thr
370 375 380
Phe Gln Gly Leu Thr Ser Leu Arg Ile Leu Asp Leu Ser Arg Asn Leu
385 390 395 400
Ile Arg Glu Ile His Ser Gly Ala Phe Ala Lys Leu Gly Thr Ile Thr
405 410 415
Asn Leu Asp Val Ser Phe Asn Glu Leu Thr Ser Phe Pro Thr Glu Gly
420 425 430
Leu Asn Gly Leu Asn Gln Leu Lys Leu Val Gly Asn Phe Lys Leu Lys
435 440 445
Asp Ala Leu Ala Ala Arg Asp Phe Ala Asn Leu Arg Ser Leu Ser Val
450 455 460
Pro Tyr Ala Tyr Gln Cys Cys Ala Phe Trp Gly Cys Asp Ser Leu Cys
465 470 475 480
Lys Leu Asn Thr Glu Asp Asn Ser Pro Gln Glu His Ser Val Thr Lys
485 490 495
Glu Lys Gly Ala Thr Asp Ala Ala Asn Val Thr Ser Thr Ala Glu Asn
500 505 510
Glu Glu His Ser Gln Ile Ile Ile His Cys Thr Pro Ser Thr Gly Ala
515 520 525
Phe Lys Pro Cys Glu Tyr Leu Leu Gly Ser Trp Met Ile Arg Leu Thr
530 535 540
Val Trp Phe Ile Phe Leu Val Ala Leu Leu Phe Asn Leu Leu Val Ile
545 550 555 560
Leu Thr Val Phe Ala Ser Cys Ser Ser Leu Pro Ala Ser Lys Leu Phe
565 570 575
Ile Gly Leu Ile Ser Val Ser Asn Leu Leu Met Gly Ile Tyr Thr Gly
580 585 590
Ile Leu Thr Phe Leu Asp Ala Val Ser Trp Gly Arg Phe Ala Glu Phe
595 600 605
Gly Ile Trp Trp Glu Thr Gly Ser Gly Cys Lys Val Ala Gly Ser Leu
610 615 620
Ala Val Phe Ser Ser Glu Ser Ala Val Phe Leu Leu Thr Leu Ala Ala
625 630 635 640
Val Glu Arg Ser Val Phe Ala Lys Asp Leu Met Lys His Gly Lys Ser
645 650 655
Ser His Leu Arg Gln Phe Gln Val Ala Ala Leu Leu Ala Leu Leu Gly
660 665 670
Ala Ala Val Ala Gly Cys Phe Pro Leu Phe His Gly Gly Gln Tyr Ser
675 680 685
Ala Ser Pro Leu Cys Leu Pro Phe Pro Thr Gly Glu Thr Pro Ser Leu
690 695 700
Gly Phe Thr Val Thr Leu Val Leu Leu Asn Ser Leu Ala Phe Leu Leu
705 710 715 720
Met Ala Ile Ile Tyr Thr Lys Leu Tyr Cys Asn Leu Glu Lys Glu Asp
725 730 735
Leu Ser Glu Asn Ser Gln Ser Ser Val Ile Lys His Val Ala Trp Leu
740 745 750
Ile Phe Thr Asn Cys Ile Phe Phe Cys Pro Val Ala Phe Phe Ser Phe
755 760 765

Ala Pro Leu Phe Thr Ala Ile Phe Ile Leu Ile Tyr Ile Met Lys Ser
770 775 780

Val Thr Leu Ile Phe Phe Ile Leu Ile Ala Tyr Leu Asn Pro Val Leu
785 790 795 800

Tyr Val Phe Phe Asn Ser Lys Phe Lys Glu Asp Trp Tyr Leu Leu Lys
805 810 815

Arg Arg Val Thr Arg Lys His Gly Ser Val Ser Val Ser Ile Ser Ser
820 825 830

Gln Gly Gly Tyr Gly Glu Gln Asp Phe Tyr Tyr Arg Cys Gly Met Tyr
835 840 845

Ser His Leu Gln Gly Asn Leu Thr Val Cys Asp Cys Cys Glu Ser Phe
850 855 860

Leu Leu Thr Lys Pro Val Ser Cys Lys His Leu Ile Lys Ser His Ser
865 870 875 880

Cys Pro Val Leu Thr Ala Ala Ser Cys Gln Arg Pro Glu Ala Tyr Trp
885 890 895

Ser Arg Cys Gly Thr Gln Ser Ala His Ser Asp Tyr Ala Asp Glu Glu
900 905 910

Arg Leu Phe Val Ser Asp Ser Ser Asp Gln Val Gln Ala Cys Gly Arg
915 920 925

Ala Cys Phe Tyr Gln Ser Arg Gly Phe Pro Leu Val Arg Tyr Ala Tyr
930 935 940

Asn Ile Gln Arg Val Arg Asp
945 950

<210> 3
<211> 2082
<212> DNA
<213> human

<400> 3
ctacatctcc ataacaatag aatccactcc ctgggaaaga aatgctttga tgggctccac 60
acccttcaga ctttagattt aaattacaat aaccttgatg aattccccac tgcaattagg 120
acattcttca acttaaagga actaggattt catagcaaca atatcaggtc gatacctgag 180
aaagcttttg taggcaaccc ttctcttatt acaatacatt tctatgacaa tcccatccaa 240
tttattggga gatctgcttt tcaacattta cctgaactaa gaacactgac tctgaatggt 300
gcctcacaaa taactgaatt tcctgattta actggaactg caaacctgga gagtctgact 360
ttaactggag cacagatctc atctcttcct caaaccctct gcaatcagtt acctaatctc 420
caagtgctag atctgtctta caacctatta gaagatttac ccagtttttc agtctgccaa 480
aagcttcaga aaattgacct aagacataat gaaatctacg aaattaaagt tgacactttc 540
cagcagttgc ttagcctccg atcgctgaat ttggcttgga acaaaattgc tattattcac 600
cccaatgcat tttccacttt gccatcccta ataaagctgg acctatcgtc caacctcctg 660
tcgtcttttc ctataactgg gttacatggt ttaactcact taaaattaac aggaaatcat 720
gccttacaga gctggatatc atctgaaaac tttccacaac tcaaggtnat agaaatgcct 780
tatgcttacc agtgctgtgc atttggagtg tgtgagaatg cctataagat ttctaatcaa 840
tggaataaag gtgacaacag cagtatggac gaccttcata agaaagatgc tggaatgttt 900
caggctcaag atgaacgtga ccttgaagat ttcctgcttg actttgagga agacctgaaa 960
gcccttcatt cagtgcagtg ttcaccttcc ccaggcccct tcaaaccctg tgaacacctg 1020
cttgatggct ggctgatcag aattggagtg tggactatag cagttctggc acttacttgt 1080
aatgctttgg tgacttcaac agttttcaga tcccctctgt acatttcccc cattaaactg 1140
ttaattgggg tcatcgcagc agtgaacatg ctcacgggag tctccagtgc cgtgctggct 1200
ggtgtggatg cgttcacttt tggcagcttt gcacgacatg gtgcctggtg ggagaatggg 1260
gttggttgcc atgtcattgg ttttttgtcc attttgcttt cagaatcatc tgttttcctg 1320
cttactctgg cagccctgga gcgtgggttc tctgtgaaat attctgcaaa atttgaaacg 1380
aaagctccat tttctagcct gaaagtaatc attttgctct gtgccctgct ggccttgacc 1440
atggccgcag ttcccctgct gggtggcagc aagtatggcg cctcccctct ctgcctgcct 1500
ttgccttttg ggagccccag caccatgggc tacatggtcg ctctcatctt gctcaattcc 1560
ctttgcttcc tcatgatgac cattgcctac acgaagctct actgcaattt ggacaaggga 1620
gacctggaga atatttggga ctgctctatg gtaaaacaca ttgccctgtt gctcttcacc 1680

aactgcatcc taaactgccc tgtggctttc ttatccttct cctctttaat aaaccttaca 1740
tttatcagtc ctcaagtaat taagtttatc cttctggtag tagtcccact tcctgcatgt 1800
ctcaatcccc ttctctacat cttgttcaat cctcacttta aggaggatct ggtgagcctg 1860
agaaagcaaa cctacgtctg gacaagatca aaacacccaa gcttgatgtc aattaactct 1920
gatgatgtcg aaaaacagtc ctgtgactca actcaagcct tggtaacctt taccagctcc 1980
agcatcactt atgacctgcc tcccagttcc gtgccatcac cagcttatcc agtcactgag 2040
agctgccatc tttcctctgt ggcatttgtc ccatgtctct aa 2082

<210> 4
<211> 693
<212> PRT
<213> human

<400> 4
Leu His Leu His Asn Asn Arg Ile His Ser Leu Gly Lys Lys Cys Phe
1 5 10 15
Asp Gly Leu His Ser Leu Glu Thr Leu Asp Leu Asn Tyr Asn Asn Leu
20 25 30
Asp Glu Phe Pro Thr Ala Ile Arg Thr Leu Ser Asn Leu Lys Glu Leu
35 40 45
Gly Phe His Ser Asn Asn Ile Arg Ser Ile Pro Glu Lys Ala Phe Val
50 55 60
Gly Asn Pro Ser Leu Ile Thr Ile His Phe Tyr Asp Asn Pro Ile Gln
65 70 75 80
Phe Val Gly Arg Ser Ala Phe Gln His Leu Pro Glu Leu Arg Thr Leu
85 90 95
Thr Leu Asn Gly Ala Ser Gln Ile Thr Glu Phe Pro Asp Leu Thr Gly
100 105 110
Thr Ala Asn Leu Glu Ser Leu Thr Leu Thr Gly Ala Gln Ile Ser Ser
115 120 125
Leu Pro Gln Thr Val Cys Asn Gln Leu Pro Asn Leu Gln Val Leu Asp
130 135 140
Leu Ser Tyr Asn Leu Leu Glu Asp Leu Pro Ser Phe Ser Val Cys Gln
145 150 155 160
Lys Leu Gln Lys Ile Asp Leu Arg His Asn Glu Ile Tyr Glu Ile Lys
165 170 175
Val Asp Thr Phe Gln Gln Leu Leu Ser Leu Arg Ser Leu Asn Leu Ala
180 185 190
Trp Asn Lys Ile Ala Ile Ile His Pro Asn Ala Phe Ser Thr Leu Pro
195 200 205
Ser Leu Ile Lys Leu Asp Leu Ser Ser Asn Leu Leu Ser Ser Phe Pro
210 215 220
Ile Thr Gly Leu His Gly Leu Thr His Leu Lys Leu Thr Gly Asn His
225 230 235 240
Ala Leu Gln Ser Trp Ile Ser Ser Glu Asn Phe Pro Glu Leu Lys Val
245 250 255
Ile Glu Met Pro Tyr Ala Tyr Gln Cys Cys Ala Phe Gly Val Cys Glu
260 265 270
Asn Ala Tyr Lys Ile Ser Asn Gln Trp Asn Lys Gly Asp Asn Ser Ser
275 280 285
Met Asp Asp Leu His Lys Lys Asp Ala Gly Met Phe Gln Ala Gln Asp
290 295 300
Glu Arg Asp Leu Glu Asp Phe Leu Leu Asp Phe Glu Glu Asp Leu Lys
305 310 315 320
Ala Leu His Ser Val Gln Cys Ser Pro Ser Pro Gly Pro Phe Lys Pro
325 330 335
Cys Glu His Leu Leu Asp Gly Trp Leu Ile Arg Ile Gly Val Trp Thr
340 345 350

Phe Asn Tyr Leu Asn Leu Thr Lys Asn Ala Leu Val Thr Met Thr Val
Phe Arg Met Ile Leu Tyr Ile Ser Pro Ile Lys Leu Leu Ile Gly Val
Ile Ala Ala Val Asn Met Leu Thr Gly Val Ser Ala Val Leu Ala Val
Gly Val Asp Ala Phe Thr Ile Gly Met Phe Ala Arg His Gly Ala Trp
Trp Asn Asn Gly Val Gly Lys His Val Ile Gly Ile Leu Ser Ile Phe
Ala Ser Glu Ser Ser Val Phe Leu Leu Thr Leu Ala Ala Leu Glu Arg
Gly Phe Ser Val Lys Tyr Ser Ala Lys Phe Glu Thr Lys Ala Pro Phe
Ser Ser Leu Lys Val Ile Ile Leu Leu Cys Ala Leu Leu Ala Leu Thr
Met Ala Ala Val Pro Leu Leu Gly Gly Ser Lys Tyr Gly Ala Ser Pro
Leu Cys Leu Pro Leu Pro Phe Gly Glu Pro Ser Thr Met Gly Tyr Met
Val Ala Leu Ile Leu Leu Asn Ser Leu Cys Phe Leu Met Met Thr Ile
Ala Tyr Thr Lys Leu Tyr Cys Asn Leu Asp Lys Gly Asp Leu Glu Asn
Ile Trp Asp Cys Ser Met Val Lys His Ile Ala Leu Leu Leu Phe Thr
Asn Cys Ile Leu Asn Cys Pro Val Ala Phe Leu Ser Phe Ser Ser Leu
Ile Asn Leu Thr Phe Ile Ser Pro Glu Val Ile Lys Phe Ile Leu Leu
Val Val Val Pro Leu Pro Ala Cys Leu Asn Pro Leu Leu Tyr Ile Leu
Phe Asn Pro His Phe Lys Glu Asp Leu Val Ser Leu Arg Lys Gln Thr
Tyr Val Trp Thr Arg Ser Lys His Pro Ser Leu Met Ser Ile Asn Ser
Asp Asp Val Glu Lys Gln Ser Cys Asp Ser Thr Gln Ala Leu Val Thr
Phe Thr Ser Ser Ser Ile Thr Tyr Asp Leu Pro Pro Ser Ser Val Pro
Ser Pro Ala Tyr Pro Val Thr Glu Ser Cys His Leu Ser Ser Val Ala
Phe Val Pro Cys Leu

<210> 5
<211> 2467
<212> DNA
<213> human

<400> 5
gaaaggaggg aaggaaaaaaa gaggaatgga aagaggacaga gaaaaggaaat aggagtggaa 60
ggagggaagg ctgctttgta actgctaaga ttgcagacag aaatagcacu caaccactgt 120
gagctgtatg ggattcagaa acgaagagcu aattttgcta actttcatta atcagttgct 180
cagataggaa gaaatgacat ctggttctat ttttttgtac atcttaattt ttggaaaata 240
ttttttctat gggagtggac aggatatgaa gtgctgcctt ggctatttcc cctgtgggaa 300
catcacaaaa tgcttgccta agctcctgcu ctgtaagagt gtggagcgat gcgggaaatg 360
agccgatgag gacaactgtg gaggacaagaa tggatggtcc atgcaatttg acaaatattt 420
tgccagttac tacaaaatga ctttcccaata tcctttttgag gcagaaagac ctggaatgttt 480

ggtcggttct gtgccagtgc aatgtctttg ccaaggtctc gaccttgact gtgatgaaac 540
caatttacga gctgttccat cctttttttc aaatctgact gcaatgtcac ttcagtggaa 600
cttaataaga aagcttcctc ctgattgctt caagaattat catgatcttc agaagctcta 660
cctgcaaaac aataagatta catccatctc catctatgct ttcagaggac tgaatagcct 720
tactaaactg tatctcagtc ataacagaat aaccttcctg aagccgggtg tttttcaaga 780
tcttcacaga ctagaatggc tgataattga agataatcac ctcagtcgaa tttcccccac 840
aacattttat ggactaaatt ctcttattct cttagtcctg atgaataacg tcctcacccg 900
tttacctgat aaacctctct gtcaacacat gccaagacta cattggctgg accttgaagg 960
caaccatatc cataatttaa gaaatttgac ttttatttcc tgcagtaatt taactgtttt 1020
agtgatgagg aaaaacaaaa ttaatcactt aaatgaaaat acttttgcac ctctccagaa 1080
actggatgaa ttggatttag gaagtaataa gattgaaaat ctttcaccgc ttatattcaa 1140
ggacctgaag gagctgtcac aattgaatct ttcctataat ccaatccaga aaattcaagc 1200
aaaccaattt gattatcttg tcaaactcaa gtctctcagc ctagaaggga ttgaaatttc 1260
aaatatccaa caaaggatgt ttagacctct tatgaatctc tctcacatat attttaagaa 1320
attccagtac tgtgggtatg caccacatgt tcgcagctgt aaaccaaaca ctgatggaat 1380
ttcatctcta gagaatctct tggcaagcat tattcagaga gtatttgtct gggttgtatc 1440
tgcagttacc tgctttggaa acctttttgt catttgcatg cgaccttata tcaggtctga 1500
gaacaagctg tatgccatgt caatcatttc tctctgctgt gccgactgct taatgggaat 1560
atatttattc gtgatcggag gctttgacct aaagtttcgt ggagaataca ataagcatgc 1620
gcagcttggg atggagagta ctcattgtca gcttgtagga tctttggcca ttctgtccac 1680
agaagtatca gttttactgt taacatttct gacattggaa aaatacatct gcattgtcta 1740
tccttttaga tgtgtgagac ctggaaaatg cagaacaatt acagttctga ttctcatttg 1800
gattactggt tttatagtgg ctttcattcc attgagcaat aaggaatttt tcaaaaacta 1860
ctatggcacc aatggagtat gcttccctct tcattcagaa gatacagaaa gtattggagc 1920
ccagatttat tcagtggcaa tttttcttgg tattaatttg gccgcattta tcatcatagt 1980
tttttcctat ggaagcatgt tttatagtgt tcatcaaagt gccataacag caactgaaat 2040
ccggaatcaa gttaaaaaag agatgatcct tgccaaacgt tttttcttta tagtatttac 2100
tgatgcatta tgctggatac ccatttttgt agtgaaattt ctttcactgc ttcaggtaga 2160
aataccaggt accataacct cttgggtagt gatttttatt ctgcccatta acagtgcttt 2220
gaacccaatt ctctatactc tgaccacaag accatttaaa gaaatgattc atcggttttg 2280
gtataactac agacaaagaa aatctatgga cagcaaaggt cagaaaacat atgctccatc 2340
attcatctgg gtggaaatgt ggccactgca ggagatgcca cctgagttaa tgaagccgga 2400
ccttttcaca tacccctgtg aaatgtcact gatttctcaa tcaacgagac tcaattccta 2460
ttcatga 2467

<210> 6
<211> 757
<212> PRT
<213> human

<400> 6
Met Thr Ser Gly Ser Val Phe Phe Tyr Ile Leu Ile Phe Gly Lys Tyr
1 5 10 15
Phe Ser His Gly Gly Gly Gln Asp Val Lys Cys Ser Leu Gly Tyr Phe
20 25 30
Pro Cys Gly Asn Ile Thr Lys Cys Leu Pro Gln Leu Leu His Cys Asn
35 40 45
Gly Val Asp Asp Cys Gly Asn Gln Ala Asp Glu Asp Asn Cys Gly Asp
50 55 60
Asn Asn Gly Trp Ser Met Gln Phe Asp Lys Tyr Phe Ala Ser Tyr Tyr
65 70 75 80
Lys Met Thr Ser Gln Tyr Pro Phe Glu Ala Glu Thr Pro Glu Cys Leu
85 90 95
Val Gly Ser Val Pro Val Gln Cys Leu Cys Gln Gly Leu Glu Leu Asp
100 105 110
Cys Asp Glu Thr Asn Leu Arg Ala Val Pro Ser Val Ser Ser Asn Val
115 120 125
Thr Ala Met Ser Leu Gln Trp Asn Leu Ile Arg Lys Leu Pro Pro Asp
130 135 140



```
Ser Ala Ile Thr Asn Thr Glu Ile Arg Asn Gln Val Lys Lys Glu Met
    610                 615                 620
Ile Leu Ala Lys Arg Phe Phe Phe Ile Val Phe Thr Asp Ala Leu Cys
625                 630                 635                 640
Trp Ile Pro Ile Phe Val Val Lys Phe Leu Ser Leu Leu Gln Val Glu
                645                 650                 655
Ile Pro Gly Thr Ile Thr Ser Trp Val Val Ile Phe Ile Leu Pro Ile
            660                 665                 670
Asn Ser Ala Leu Asn Pro Ile Leu Tyr Thr Leu Thr Thr Arg Pro Phe
        675                 680                 685
Lys Glu Met Ile His Arg Phe Trp Tyr Asn Tyr Arg Gln Arg Lys Ser
    690                 695                 700
Met Asp Ser Lys Gly Gln Lys Thr Tyr Ala Pro Ser Phe Ile Trp Val
705                 710                 715                 720
Glu Met Trp Pro Leu Gln Glu Met Pro Pro Glu Leu Met Lys Pro Asp
                725                 730                 735
Leu Phe Thr Tyr Pro Cys Glu Met Ser Leu Ile Ser Gln Ser Thr Arg
            740                 745                 750
Leu Asn Ser Tyr Ser
        755
```

<210> 7
<211> 3584
<212> DNA
<213> human

<400> 7

```
ctgctttgta actgctaaga ttgcagacag aaatagcaca caaccactgt gagctgtatg      60
cgattcagaa accaagacca aattttgctc actttcatta atcagttgct cagatagaag     120
gaaatgacat ctggttctgt cttcttctac atcttaattt ttggaaaata ttttttctcat     180
gggggtggac aggatgtcaa gtgctccctt ggctatttcc cctgtgggaa catcacaaag     240
tgcttgcctc agctcctgca ctgtaacggt gtggacgact gcgggaatca ggccgatgag     300
gacaactgtg tggtggtttt gtgccagtgc atgtctttgc caggtctgga gcttgactgg     360
atgaaaccat ttacgagtgt tccatcggtt tcttcaaatg tgactgcaat gtcacttcag     420
tggaacttaa taagaaagct tcctcctgat tgcttcaaga attatcatga tcttcagaag     480
ctggacctgc aaaacaataa gattacatcc atctccatct atgctttcag aggactgaat     540
agccttacta aactgtatct cagtcataac agaataacct tcctgaagcc gggtgttttt     600
gaagatcttc acagactaga atggctgata attgaagata atcacctcag tcgaatttcc     660
ccaccaacat tttatggact aaattctctt attctcttag tcctgatgaa taacgtcctc     720
acccgtttac ctgataaacc tctctgtcaa cacatgccaa gactacattg gctggacctt     780
gaaggcaacc atatccataa tttaagaaat ttgactttta tttcctgcag taatttaact     840
gttttagtga tgaggaaaaa caaaattaat cacttaaatg aaaatacttt tgcacctctc     900
cagaaactgg atgaattgga tttaggaagt aataagattg aaaatcttcc accgcttata     960
ttcaaggacc tgaaggagct gtcacaattg aatctttcct ataatccaat ccagaaaatt    1020
caagcaaacc aatttgatta tcttgtcaaa ctcaagtctc tcagcctaga agggattgaa    1080
atttcaaata tccaacaaag gatgtttaga cctcttatga atctctctca catatatttt    1140
aagaaattcc agtactgtgg gtatgcacca catgttcgca gctgtaaacc aaacactgat    1200
ggaatttcat ctctagagaa tctcttggca agcattattc agagagtatt tgtctgggtt    1260
gtatctgcag ttacctgctt tggaaacatt tttgtcattt gcatgcgacc ttatatcagg    1320
tctgagaaca agctgtatgc catgtcaatc atttctctct gctgtgccga ctgcttaatg    1380
ggaatatatt tattcgtgat cggaggcttt gacctaaagt ttcgtggaga atacaataag    1440
catgcgcagc tgtggatgga gagtactcat tgtcagcttg taggatcttt ggccattctg    1500
tccacagaag tatcagtttt actgttaaca tttctgacat tggaaaaata catctgcatt    1560
gtctatcctt ttagatgtgt gagacctgga aaatgcagaa caattacagt tctgattctc    1620
atttggatta ctggttttat agtggctttc attccattga gcaataagga atttttcaaa    1680
aactactatg gcaccaatgg agtatgcttc cctcttcatt cagaagatac agaaagtatt    1740
ggagcccaga tttattcagt ggcaattttt cttggtatta atttggccgc atttatcatc    1800
atagtttttt cctatggaag catgttttat agtgttcatc aaagtgccat aacagcaact    1860
gaaatacgga atcaagttaa aaaagagatg atccttgcca aacgtttttt ctttatagta    1920
```

```
ttacttgatc cattatttgt tatattcatt ttttagtgaa atttttttta ttatcttcag    1980
gtagaaatac taggtacctt aacctcttgg gtagtgattt ttattctgcc tattaacagt    2040
actttgaacc caattttcta tactctgacc acaagaccat ttaaagaaat gattcatcgg    2100
ttttggtata actacagaca aagaaaatct atggacagca aagctcagaa aacatatgct    2160
ccatcattca tctggtggga aatgtgacca ctgcaggaga tgccacctga gttaatgaag    2220
ccggaccttt tcacatacct ccttgaaatc tcactgattt ctcagtcaac gagactcaat    2280
tcctattcat gactgactct gaaattcatt tctttgcaga gaatactgtc gggctgcttc    2340
atgagggatt tactggtatc aaaatgaata ccacaaaatt aatttataat aatagctaag    2400
ataaatattt tacaaggaca tgaggaaaaa taaaaatgac taatgctctt acaaagggaa    2460
gtaattatat caataatcta tatatattag tagacatttt gcataagaaa ttaagagaaa    2520
tctacttcag taacattcat tcatttttct aacatgcatt tattgactac ccactactat    2580
gtgcatagca ttgcaatata gtcctggaag tagacagtgc agaacctttc aatctgtaga    2640
tagtgtttaa tgacaaaaga ctatacaaag tccatctgca gttcctagtt taaagtagag    2700
ctttacctgt catgtgcatc agcaagaatc ataggcactt ttaaataaag gtttaaagtt    2760
ttggaatact cagtgtattt gcatcataga aaatgtctga ctgtttgcaa aataatattc    2820
tgttttaaga atccatctta ctctctttta agtttccata cacttgagag ccaacacaac    2880
atatttatta ctaaaaagat gctttgctag aaactcaaaa acagcacttc ttttggcact    2940
tcctgcccag ttttctcttt gctttaaatg aacatcatca tatggaattg gaataggaga    3000
gtatgagtac ggcagagaag tggatcagaa aaactagaat gaggataaac atttacatta    3060
gtggaaactc ctgaaataaa tccttgtatt gtcagttaac tgatttcaa caaggatgcc    3120
aagacaaaaa ggcttttcaa caaaccgtgc tgttttaaga acagacctaa gtggtttaat    3180
tcacccactt tagatgggtg aatgttatgg tgtgtgaaat atctcagtaa agcagttaaa    3240
aggaaaaaga gctggaatgc actgattcag gaacttaatt tcaggaagga aaggtctgta    3300
tgtacacatt tcactttaag cagaaaatct ttcttcaaga aatgacttta cttttctttt    3360
gcactgccag cacgtgagat actaactttt taactagttg ttcttctcta gtctctacgt    3420
tattagnatt ttttgctttc ataatgtgaa acctttaagc aggagaagaa aatgttttca    3480
gatagtttca aatacnccaa aaatgtttgc aacacaaaaa tactggaatc naaccataat    3540
gcccttattg aatatatagt tgtatagntt tgttctgaaa accc                     3584

      <210> 8
      <211> 722
      <212> PRT
      <213> human

      <400> 8
Met Thr Ser Gly Ser Val Phe Phe Tyr Ile Leu Ile Phe Gly Lys Tyr
 1               5                  10                  15
Phe Ser His Gly Gly Gly Gln Asp Val Lys Cys Ser Leu Gly Tyr Phe
            20                  25                  30
Pro Cys Gly Asn Ile Thr Lys Cys Leu Pro Gln Leu Leu His Cys Asn
        35                  40                  45
Gly Val Asp Asp Cys Gly Asn Gln Ala Asp Glu Asp Asn Cys Val Val
    50                  55                  60
Val Leu Cys Gln Cys Met Ser Leu Pro Gly Leu Glu Leu Asp Trp Met
65                  70                  75                  80
Lys Pro Phe Thr Ser Val Pro Ser Val Ser Ser Asn Val Thr Ala Met
                85                  90                  95
Ser Leu Gln Trp Asn Leu Ile Arg Lys Leu Pro Pro Asp Cys Phe Lys
            100                 105                 110
Asn Tyr His Asp Leu Gln Lys Leu Asp Leu Gln Asn Asn Lys Ile Thr
        115                 120                 125
Ser Ile Ser Ile Tyr Ala Phe Arg Gly Leu Asn Ser Leu Thr Lys Leu
    130                 135                 140
Tyr Leu Ser His Asn Arg Ile Thr Phe Leu Lys Pro Gly Val Phe Glu
145                 150                 155                 160
Asp Leu His Arg Leu Glu Trp Leu Ile Ile Glu Asp Asn His Leu Ser
                165                 170                 175
Arg Ile Ser Pro Pro Thr Phe Tyr Gly Leu Asn Ser Leu Ile Leu Leu
            180                 185                 190
```

Val Leu Met Asn Asn Thr Leu Thr Arg Leu Ile Arg Lys Ile Leu Leu Cys
195 200 205
Gln His Met Ile Asn Leu His Trp Leu Asp Leu Glu Gly Asn His Ile
210 215 220
His Asn Leu Arg Asn Leu Thr Phe Ile Ser Cys Ser Asn Leu Thr Val
225 230 235 240
Leu Val Met Arg Lys Asn Lys Ile Asn His Leu Asn Glu Asn Thr Phe
245 250 255
Ala Pro Leu Gln Lys Leu Asp Glu Leu Asp Leu Gly Ser Asn Lys Ile
260 265 270
Glu Asn Leu Pro Pro Leu Ile Phe Lys Asp Leu Lys Glu Leu Ser Gln
275 280 285
Leu Asn Leu Ser Tyr Asn Pro Ile Gln Lys Ile Gln Ala Asn Gln Phe
290 295 300
Asp Tyr Leu Val Lys Leu Lys Ser Leu Ser Leu Glu Gly Ile Glu Ile
305 310 315 320
Ser Asn Ile Gln Gln Arg Met Phe Arg Pro Leu Met Asn Leu Ser His
325 330 335
Ile Tyr Phe Lys Lys Phe Gln Tyr Cys Gly Tyr Ala Pro His Val Arg
340 345 350
Ser Cys Lys Pro Asn Thr Asp Gly Ile Ser Ser Leu Glu Asn Leu Leu
355 360 365
Ala Ser Ile Ile Gln Arg Val Phe Val Trp Val Val Ser Ala Val Thr
370 375 380
Cys Phe Gly Asn Ile Phe Val Ile Cys Met Arg Pro Tyr Ile Arg Ser
385 390 395 400
Glu Asn Lys Leu Tyr Ala Met Ser Ile Ile Ser Leu Cys Cys Ala Asp
405 410 415
Cys Leu Met Gly Ile Tyr Leu Phe Val Ile Gly Gly Phe Asp Leu Lys
420 425 430
Phe Arg Gly Glu Tyr Asn Lys His Ala Gln Leu Trp Met Glu Ser Thr
435 440 445
His Cys Gln Leu Val Gly Ser Leu Ala Ile Leu Ser Thr Glu Val Ser
450 455 460
Val Leu Leu Leu Thr Phe Leu Thr Leu Glu Lys Tyr Ile Cys Ile Val
465 470 475 480
Tyr Pro Phe Arg Cys Val Arg Pro Gly Lys Cys Arg Thr Ile Thr Val
485 490 495
Leu Ile Leu Ile Trp Ile Thr Gly Phe Ile Val Ala Phe Ile Pro Leu
500 505 510
Ser Asn Lys Glu Phe Phe Lys Asn Tyr Tyr Gly Thr Asn Gly Val Cys
515 520 525
Phe Pro Leu His Ser Glu Asp Thr Glu Ser Ile Gly Ala Gln Ile Tyr
530 535 540
Ser Val Ala Ile Phe Leu Gly Ile Asn Leu Ala Ala Phe Ile Ile Ile
545 550 555 560
Val Phe Ser Tyr Gly Ser Met Phe Tyr Ser Val His Gln Ser Ala Ile
565 570 575
Thr Ala Thr Glu Ile Arg Asn Gln Val Lys Lys Glu Met Ile Leu Ala
580 585 590
Lys Arg Phe Phe Phe Ile Val Phe Thr Asp Ala Leu Cys Trp Ile Pro
595 600 605
Ile Phe Val Val Lys Phe Leu Ser Leu Leu Gln Val Glu Ile Pro Gly
610 615 620
Thr Ile Thr Ser Trp Val Val Ile Phe Ile Leu Pro Ile Asn Ser Ala
625 630 635 640
Leu Asn Pro Ile Leu Tyr Thr Leu Thr Thr Arg Pro Phe Lys Glu Met
645 650 655

Ile His Arg Ile Trp Tyr Asn Tyr Arg Thr Arg Tyr Met Met Asp Ser
660 665 670
Lys Gly Gln Lys Thr Tyr Ala Pro Ser Ile Ile Trp Val Glu Met Trp
675 680 685
Pro Leu Gln Glu Met Pro Pro Glu Leu Met Lys Pro Asp Leu Phe Thr
690 695 700
Tyr Pro Cys Glu Met Ser Leu Ile Ser Gln Ser Thr Arg Leu Asn Ser
705 710 715 720
Tyr Ser

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/06573

A. CLASSIFICATION OF SUBJECT MATTER
IPC(6) :C07K 14/705; C12N 15/12, 15/63, 15/70, 15/79
US CL :530/350; 435/69.1, 252.3, 254.11, 320.1, 325
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 435/69.1, 252.3, 254.11, 320.1, 325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Biosis, Medline, WPI
search terms: G-protein coupled receptor, Leucine rich repeats, Gonadotropin receptor, Thyrotropin receptor

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,614,363 A (CONE) 25 March 1997, entire document.	1-11
X, P ----- Y, P	US 5,858,716 A (ELSHOURBAGY et al.) 12 January 1999, columns 20-30, entire document.	11 ----- 1-10
X -- Y	HWANG et al. Analysis of Expressed Sequence Tags from a Fetal Human Heart cDNA Library. Genomics. 1995, Vol. 30, pages 293-298, entire document.	5, 7, 11 -------- 1-4, 6, 8-10

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 11 JUNE 1999	Date of mailing of the international search report 02 AUG 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Sally P. Teng Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No
PCT/US99/06573

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-11, drawn to nucleic acids encoding LGR4, the LGR4 polypeptide, and method of using the LGR4 nucleic acid.
Group II, claims 1-11, drawn to nucleic acids encoding LGR5, the LGR5 polypeptide and method of using the LGR5 nucleic acid.
Group III, claims 1-11, drawn to nucleic acid encoding LGR6, the LGR6 polypeptide, and method of using the LGR6 nucleic acid.
Group IV, claims 12 and 13, drawn to antibody that binds to LGR4.
Group V, claims 12 and 13, drawn to antibody that binds to LGR5.
Group VI, claims 12 and 13, drawn to antibody that binds to LGR7.
Group VII, claims 14-17, drawn to transgenic animal model containing an altered LGR4 gene.
Group VIII, claims 14-17, drawn to transgenic animal model containing an altered LGR5 gene
Group IX, claims 14-17, drawn to transgenic animal model containing an altered LGR7 gene
Group X, claim 18, drawn to a method of screening for a ligand for LGR4.
Group XI, claim 18, drawn to a method of screening for a ligand for LGR5.
Group XII, claim 18, drawn to a method of screening for a ligand for LGR7.

Each of the claims 1-18 is in three different groups because LGR4, LGR5, and LGR7 are structurally and functionally distinct polypeptides.

The inventions listed as Groups I-XII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of Group I is the nucleic acid sequence encoding LGR4. The special technical feature of Group II is the nucleic acid sequence encoding LGR5. The special technical feature of Group III is the nucleic acid sequence encoding LGR7. The special technical feature of Group IV is the antibody that binds to LGR4 but does not have the amino acid sequence of LGR4. The special technical feature of Group V is the antibody that binds to LGR5 but does not have the amino acid sequence of LGR5. The special technical feature of Group VI is the antibody that binds to LGR6 but does not have the amino acid sequence of LGR6. The special technical feature of Group VII is a transgenic animal containing an altered LGR4 gene. The special technical feature of Group VIII is a transgenic animal containing an altered LGR5 gene. The special technical feature of Group IX is a transgenic animal containing an altered LGR7 gene. The special technical feature of Group X is a method of screening for a ligand that binds LGR4.
The special technical feature of Group XI is a method of screening for a ligand that binds LGR5. The special technical feature of Group XII is a method of screening for a ligand that binds LGR7. The special technical feature of each group is not the same or does not correspond to the special technical feature of any other group because the products of Groups I-IX are structurally and functionally distinct and the methods of Groups I-III and X-XII are distinct methods of using different starting reagent for accomplishing different goals. The groups are not linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/06573

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	HSU et al. Charcterization of Two LGR Genes Homologous to Gonadotropin and Thyrotropin Receptors with Extracelllular Leucine-Rich Repeats and a G Protein-Coupled, Seven Transmembrane Region. Molecular Endocrinology. December 1998, Vol. 12, No. 12, pages 1830-1845, especially pages 1831-1837.	1-11